National + International Research Studies & Trials
Help medical researchers learn as much as possible about COVID-19 by participating in these national studies, open to people across the United States and in various other countries. Many are surveys and data collection studies. Please also check listings for studies that are U.S. state specific.
United States
Family-Centered Mental Health Survey: An Inquiry into the Support of Families of Critical Care Patients [Remote]
The purpose of this survey is to understand the personal experiences and mental health of family members who have/had loved ones in the intensive care unit (ICU) or any other critical healthcare facility related to any disease or health problem.
The survey is composed of 38 questions that should take 10-15 minutes to complete.
You are NOT required to provide any personal information. Your responses are 100% anonymous and confidential. If you would like to participate in a raffle for an Amazon Gift Card, you will need to provide your email address at the end of the survey, but this is completely voluntary.
This study is approved by the University of Kentucky, Institutional Review Board and Protection of Human Subjects in Clinical Trials. (IRB #83549, Approval Expires: 11/29/2023)
Contact: Dr. A. Faiola | anthonyfaiola@uky.edu
Arizona Community Engagement and Alliance Consortium (AZ CEAL) COVID Peer-to-Peer Program [Remote]
Description: The COVID pandemic has caused a greater risk of hospitalizations and deaths in individuals belonging to racial/ethnic minorities and individuals with fewer resources. Such greater risk may be due to a lack of resources, health information, or mistrust. Treating COVID and its consequences (such as Long COVID) needs quick action to improve knowledge about Long COVID and information regarding health services and disability resources.
The purpose of the study is to provide information to people who are experiencing symptoms for more than 30 days after their COVID infection about the resources which are available to them.
Specifically, the study aims to provide Long COVID participants with support in regard to their understanding of their (1) symptoms, (2) where to find Long COVID treatment facilities and clinical trial participation opportunities, and (3) refer patients to long COVID disability resources (4) COVID vaccine accessibility.
For this study, a peer mentor will be paired with a peer mentee and they can communicate to receive support via phone call system.
Contact: Lidia Azurdia Sierra, MPH | lazurdia@arizona.edu
Nina Santa Cruz | nssantacruz1@arizona.edu
For more information, please call or text: 520-542-2970.
Diet and Fasting for Long COVID [Remote]
This is a research study to explore the potential of a low sugar diet, daily time-restricted eating and periodic one or two day water fasts to gradually reduce the severity of long COVID symptoms over time. The study is a response to the unmet need for treatments that address the constellation of symptoms associated with Long COVID.
This research study is being led by Jeffrey Novack PhD of Pacific Northwest University of Health Sciences in collaboration with Thomas Bunker, PhD.
The duration of the study is 10 weeks. The study will be conducted as follows:
6 weeks : No added sugars diet, eat in a 10 to 12 hour window daily
4 weeks : No added sugars diet, eat in an 8 hour window daily, 36 or 60 water fasts weekly
Researchers are seeking to determine whether or not specific diets and/or fasts are effective at reducing twenty-eight common long-covid symptoms.
Eligibility Criteria:
Must be 18 to 69 years old.
Must reside in the United States.
Must have at least five common long COVID symptoms.
Must be willing to follow a no sugar diet and daily time-restricted eating.
Must be willing to try one or two day water fasts.
Must be willing to limit certain supplements that may interfere with the periodic induction of cellular housecleaning (aka autophagy).
Must have had long COVID symptoms for at least 45 days.
The study will take place remotely via video calls, and via e-mail and surveys.
To see if you qualify, take the Initial Screening Survey below: https://redcap.pnwu.edu/redcap/surveys/?s=ETJRPTE4MATCMJND
Contact: Thomas Bunker, PhD | 720-470-1046
Share your Experience of Living with Long COVID [Remote]
The purpose of this study, led by graduate students at California State University Dominguez Hills, is to better understand the experience of people living with long COVID and those who support them.
The study will consist of a 30-60 minute interview over the phone or through Zoom. There will be an option to provide photos that represent your long COVID experience.
You are eligible for this study if you are:
Living with long COVID or supporting someone living with long COVID
Between 18-65 years old
If you are interested in participating in this study, please email Carly Wong at cwong53@toromail.csudh.edu.
The COVID Journey | A Stanford Research Study [Remote]
The objective of The COVID Journey research project is to tell the story of American healthcare during the pandemic, especially with regards to telehealth care services. The project team is seeking 30 individuals in 5 racial/ethnic groups (Latine, African American, Asian, Native American, Caucasian) who had moderate-severe COVID-19 to share their significant healthcare/telehealth experiences with us.
The stories of these individuals will be used to identify care gaps and develop care solutions. These stories will help us shed light on issues in the modern healthcare system and give voice to those whose voices have not traditionally been part of the healthcare conversation. Participants will be paid for their time with a $75 honorarium.
The main eligibility criteria for this project are:
Had moderate-severe COVID (requiring communication with health professionals)
Age 18 years or older
In particular, we are eager to recruit participants with dementia or autism or that identify with the African American or Hispanic communities (we welcome intersectional identities and other participant demographics as well)
This research project will take place over the computer or phone (and the interview time will be scheduled around the participant's availability). Participants will complete an initial screening survey to make sure they are a good fit for the study and then will participate in a 1-2 hour interview. Participants also have the opportunity to participate in an optional photoshoot (the photoshoot is not required to participate in or be compensated for the study).
Contact: Email covidjourney@stanford.edu or call 650-497-9567.
Cognitive Outcomes of Individuals Who Tested Positive for COVID-19 [Remote]
Yale University Medical School and the Illinois Institute of Technology are collaborating to study the impact of COVID-19 infection on cognitive function.
Study participants will be asked to complete questionnaires about their medical history and mood and behavior. In addition, participants will be asked to complete an online neuropsychological test from a website called “testmybrain.” The study is currently being launched to obtain cross-sectional data with hopes of one day obtaining in-person neuropsychological measurements.
All participants will be added to a 50$ raffle.
Eligibility: The study is seeking to recruit individuals from the age of 18-65 who have no diagnosis of neurocognitive impairment.
Contact: Jared Cherry | sociallyconsciouslab@gmail.com
The Impact of Long COVID-19 on Attention and Other Aspects of Cognition [Remote]
The purpose of this study is to investigate the effects of long COVID on cognition, specifically memory and attention. Study participants will attend one 90 minute virtual appointment to assess memory and attention domains.
Adults 18 to 65 years old without a diagnosis of COVID-19 and those with a diagnosis of COVID-19 who were not hospitalized during their illness are eligible to participate in this study.
The study team is offering a gift card lottery entry for participants to win 1 of 10 $75.00 gift cards.
If you are interested in participating in this study, please follow the following link: https://fielding.az1.qualtrics.com/jfe/form/SV_cOdlXlZuHMwS9EO
Contact: Dr. Jessica PIller, Fielding Graduate University | (530) 656-8372
Balance Confidence and Fall Risk in Older Adults with Long-Haul COVID-19 [Remote]
Researchers at Western Washington State University are exploring whether fall risk and balance confidence are affected by having COVID and/or long-haul COVID in older adults.
Participants will complete an online survey that asks demographic questions, as well as questions about COVID-19 infection and long-haul COVID status. Then, they will complete two short, validated surveys about their concern about falling during basic daily activities. It should take about 20-30 minutes.
The study is looking for participants who:
Currently have Long-Haul COVID
Had COVID-19 but NOT Long-Haul COVID
Never had COVID-19
Participants must be U.S. residents between the ages of 65 years and 90 years. They should know their current or prior COVID-19 infection based on one or more tests. If they had COVID-19, they should know approximately how long they've had symptoms.
Contact: Mariel Relyea | relyeam@wwu.edu
Global Consortium of Chemosensory Research (GCCR) Phytochemical Project Survey [Remote]
During the pandemic, many people have tried various methods to help accelerate recovery from COVID-19, from the chemosensory dysfunction caused by COVID-19, and from the long-hauler symptoms following the acute phase of COVID-19.
One of the most popular approaches is to eat and drink ‘healthy’ or medicinal foods and drinks. There are many foods and drinks known to contain plant-based chemical compounds (phytochemicals) with anti-inflammatory effects and binding affinity with SARS-CoV-2 virus.
The researchers involved in this study would like to investigate whether eating and drinking habits affect recovery from the symptoms of COVID-19, including COVID-19- induced chemosensory dysfunction. We have developed a survey to address these questions. Participants will be asked what types of food they ate and drank, herbal medicines and supplements they took, and essential oils they used.
It will take about 10 min to go through the survey. Data will be de-identified.
Links to the survey in different languages:
Chinese: https://www.wcrcnet.cn/redcap/surveys/?s=E4ERRTX9Y9KY9ER8
English: https://iu.co1.qualtrics.com/jfe/form/SV_b1uraeoXtX8i5rU
Italian: https://iu.co1.qualtrics.com/jfe/form/SV_1WYXdwObhEk3ZOK
Indian English: https://iu.co1.qualtrics.com/jfe/form/SV_1Hdew0OAB9LLz8i
Japanese: https://iu.co1.qualtrics.com/jfe/form/SV_b2ZcH964YcOKVZY
Russian: https://iu.co1.qualtrics.com/jfe/form/SV_07iicETGShlwwwS
Spanish: https://iu.co1.qualtrics.com/jfe/form/SV_eRGhK6nd5I65IJ8
Polish: https://iu.co1.qualtrics.com/jfe/form/SV_bQH8yb6aygMb6N8
Eligibility: Participants must be over 18 years of age.
Contact: If you have any questions about the survey, please contact:
Thomas Heinbockel, Ph.D., Howard University, theinbockel@howard.edu
Paule Joseph, Ph.D., NIH/NIAAA, paule.joseph@nih.gov
Sachiko Koyama, Ph.D., Indiana University, sakoyama@iu.edu
Vonnie Shields, Ph.D., Towson University, vshields@towson.edu
Patient-Led Research Collaborative Study #1: Prolonged Recovery from COVID-19 – Impacts from Vaccination [Remote]
The goal of the Patient-Led Research Collaborative is to collect data on those with COVID-19 prolonged recoveries and distribute that information to both the general public and to medical professionals.
If you are at least 5 weeks past your final vaccine dose, you are encouraged to take the Prolonged Recovery from COVID-19 – Impacts from Vaccination survey. This survey is open to everyone – to people with Long COVID, those who had COVID but not Long COVID, and those who never had COVID.
This survey has IRB approval through University College London (UCL).
Contact: team@patientresearchcovid19.com
Patient-Led Research Collaborative Study #2: Online Survey on Recovery from COVID-19 [Remote]
The goal of the Patient-Led Research Collaborative is to collect data on those with COVID-19 prolonged recoveries and distribute that information to both the general public and to medical professionals.
The Online Survey on Recovery from COVID-19 will be examining the antibody testing results of those who have previously contracted COVID-19 infection as well as wider and more detailed symptoms, including neurological, cardiovascular, systemic and beyond, in addition to the impact on mental health.
The survey is available in the following languages: Russian, French, Dutch, Spanish, Italian, Portuguese, Indonesian, and Arabic.
This survey is sponsored by University College London (UCL).
The Collaborative invites you to take part in this study if you:
Previously experienced or are currently experiencing symptoms consistent with COVID-19
Have a suspected or confirmed SARS-CoV-2 infection
Are over 18 years of age
Contact: Athena Akrami, PhD; Sainsbury Wellcome Centre for Neural Circuits and Behaviour, UCL | athena.akrami@ucl.ac.uk
Covid-19 Virtual Recovery Study [Remote]
The purpose of this study is to determine the effects of respiratory muscle training (RMT) and nasal breathing on patients who have been infected with the SARS-CoV2 virus and continue to have lingering symptoms.
This study will be conducted virtually and will be completed at home using a cell phone application. Study participation involves the use of a RMT device, and/or nasal breathing. The purpose of this research is to evaluate the impact of RMT and nasal breathing on chronic symptoms of COVID-19 in patients that have recovered from SARS-CoV2.
Inclusion criteria:
Positive test for SARS-CoV2 within the last 3 months.
Smartphone user.
English speaker.
Age 18 or above.
US resident.
Exclusion criteria:
Hemodynamic instability.
Contraindications or inability to perform RMT.
Inability to navigate study questionnaires or tasks.
History of kidney disease, arteriosclerosis obliterans, and high calcium levels.
Contact: Meredith Shea, PhD | 480-301-60211| shea.meredith@mayo.edu
Whitman College Wellness Study: Assessing Care Innovation and Wellness and Measuring the Value of Peer Support Alongside Medical Care [Remote]
Researchers at Whitman College are conducting an IRB-approved research study to assess the effectiveness of personal health narratives and peer support. The Wellness Study works to develop and test the effectiveness of online self-advocacy and self-health platforms which are to be used in parallel with existing healthcare treatment.
The Wellness Study will provide a complement of tools to increase self-health for those suffering from Long COVID and other chronic illnesses. More specifically, this will include storytelling, peer networking, exchanging health resources, and asking for assistance.
The Wellness Study was developed with patient disenfranchisement from the health system and unreasonable provider demands in mind before COVID-19 struck. The pandemic has accentuated the value of peer support to combat health inequities and injustices, caregiver burdens, and deficiencies of healthcare-for-profit. Potential benefits of peer support include increased connection with others, self-confidence, empathy, and personal agency. Additionally, engaging confidentially with others who have similar lived experiences encourages resilience through the emotional impacts of Long Covid and other chronic illnesses.
The Wellness Study is spearheaded by Kinnected: a free, multi-sided platform that offers multiple avenues and tools for members to anonymously connect and support one another around physical, emotional, and social health. The study will be conducted in partnership with Whitman College to maintain the integrity of the study by providing distance from those with bias relating to the study’s potential for success.
Inclusion criteria: Patients with post-acute sequelae SARS-CoV-2 infection (PASC) or chronic conditions such as fibromyalgia, Lyme disease, and chronic pain.
Contact Researchers: Suzanne Morrissey, PhD, Stephanie Hillman, MNPL and Sara Little |
Email: wellnessstudy@whitman.edu
COVID-19 Recovery Study: Symptoms and Biomarkers of Long COVID-19 in People Living With and Without HIV
This is a prospective observational study being conducted to learn about late (2+ weeks or more) effects of COVID-19 in people living with and without HIV. The investigators plan to do this by studying people who have COVID-19 and people who have not had COVID-19, and by studying people living with HIV and people who are HIV-negative. The investigators will investigate the average duration of symptoms after COVID-19, how these symptoms affect quality of life, and what medical complications are common after COVID-19 in people with and without HIV.
Participation involves:
Participant completion of surveys about themselves, their health history, their quality of life and mood in the recent past, and about COVID-19 or HIV if the participant has a history of either infection. The investigators will ask participants to answer questions in up to 5 follow-up surveys over the course of a year about their symptoms, mood, quality of life, and changes in health. Participants will also complete a series of short tests of thinking, memory, and reaction speed at certain follow-up surveys.
Up to two visits to the participant's home (or an acceptable location of their choosing) by a phlebotomist. The phlebotomist will collect about 3.5 tablespoons of blood, as well as measure height, weight, and vital signs when laying down and standing up.
This is a fully remote study and all study activities can be done from home or another location of the participant's choosing.
Investigators will recruit volunteers with and without HIV and with and without a COVID-19 diagnosis from across the contiguous 48 US states in the following numbers:
110 adult people living with HIV (PWH) with COVID-19 symptom onset or first positive test within the prior 4 months
110 adult HIV-negative people with COVID-19 symptom onset or first positive test within the prior 4 months
45 adult PWH with no history of COVID-19
50 adult HIV-negative people with no history of COVID-19
Investigators aim to enroll a population of PWH that is roughly representative of the demographic and geographic diversity of PWH across the United States.
Inclusion Criteria:
Adults 18 years of age or older
Living within the contiguous 48 states
Groups 1 and 3: self-reported HIV infection
Groups 2 and 4: self-reported HIV negative
Exclusion Criteria:
Inability to communicate by telephone in English or Spanish
Inability to complete required study events
A first or only diagnosis of COVID-19 5 or more months prior to first contact with participant
Groups 3 and 4: diagnosis of cOVID-19 ever, or participant suspects they had COVID-19 at any time regardless of whether they were tested
Contacts: Nuria Gallego Marquez, MSPH | covidrecovery@jhmi.edu
Annie Antar, MD, PhD | covidrecovery@jhmi.edu
ProterixBio Investigational At-Home COVID-19 Antibody Test [Remote]
ProterixBio is looking for volunteers to help them evaluate the performance and usability of the ProterixBio finger stick dried blood spot collection kit to help investigators develop a COVID-19 antibody test using blood sampled in the home. This is not a drug treatment study. The study will use the ProterixBio collection kit to obtain a blood sample from volunteers to evaluate antibody levels in their blood using this investigational device. Volunteers will receive a $ 50 gift card after completing the sample collection.
Inclusion Criteria:
Are 18 years of age or older
Are able to read/view instructions
Are not vaccinated with:
No prior COVID-19 infection
With prior COVID-19 infection AND positive PCR test
Contact: Text (857) 242-0474 or fill out the online sign-up form.
Global Consortium Chemosensory Research Studies [Remote]
Global Consortium Chemosensory Research (GCCR) is a group of 600 scientists, clinicians, and patient advocates across 50 countries founded in response to the COVID-19 pandemic. The goal of GCCR is to collect evidence-based information to combat the spread of COVID-19. Research from GCCR has revealed that while many people recover from COVID-19 related symptoms after a few weeks, about as many patients suffer from persistent smell and taste changes following COVID-19 disease. If you are experiencing this form of smell and/or taste loss following COVID-19 and would like to participate in a study aimed to understand the mechanics behind long-term COVID-19-related smell and taste loss by tracking changes and/or recovery in these symptoms, then you are encouraged to sign up for the new GCCR study. Participants will be asked to smell and taste a few items from their own kitchen, in their own homes and track results using their personal devices.The study takes about 20 minutes to complete, and participants will be asked to complete this task 9 times; after each time, participants will be able to see the changes in their sense of smell and taste.
Contact Researchers:
Kathrin Ohla (info@riech-check.de)
John Hayes (jeh40@psu.edu)
Kathrin Ohla (info@riech-check.de)
Understanding COVID-19 recovery trajectories in people living with and without HIV
If there is a person you know of who has recently been diagnosed with SARS-CoV-2 infection of any severity (in the prior 4 weeks), please let them know that there is an amfAR research study to understand COVID recovery in people with and without HIV that can be completed entirely from their home/residence and offers $50. Participants complete surveys and blood draws from home. A mobile phlebotomist from ExamOne will come to the participant’s home or other location of their choosing for blood draws.
Study entry is open to people who are HIV+ or HIV-, English or Spanish speakers (se habla español!). Participants can reside anywhere in the contiguous 48 United States.
Interested individuals may learn more by contacting the study via:
Email: COVIDRecovery@jhmi.edu
Website: www.CovidRecoveryStudy.org
Phone: (443) 961-4681.
Principal Investigator: Dr. Annie Antar, Johns Hopkins.
Co-Investigators: Dr. Alan Landay, Rush University, Dr. Michael Peluso, UCSF.
Investigando las trayectorias de recuperación del COVID en personas que viven con y sin VIH
Si conoce a una persona que recientemente ha sido diagnosticada con una infección por SARS-CoV-2 de cualquier gravedad (en las 4 semanas anteriores), hágale saber que hay una investigación de amfAR estudio para comprender la recuperación de COVID en personas sin y con VIH que se puede completar completamente desde su hogar / residencia y ofrece $ 50. Los participantes completan encuestas y extracciones de sangre desde casa, por lo que la carga para los participantes es baja. Un flebotomista móvil de ExamOne irá a la casa del participante u otro lugar de su elección para la extracción de sangre.
La elegibilidad del estudio está abierta a personas que son VIH + o VIH-, que hablan inglés o español. Los participantes pueden residir en cualquier lugar de los 48 estados contiguos de Estados Unidos.
Las personas interesadas pueden obtener más información poniéndose en contacto con el estudio:
Correo electrónico: COVIDRecovery@jhmi.edu
Sitio web: www.CovidRecoveryStudy.org
Teléfono (443) 961-4681.
Investigador principal: Dra. Annie Antar, Johns Hopkins.
Co-investigadores: Dr. Alan Landay, Rush University, Dr. Michael Peluso, UCSF.
A study to understand the long term outcomes of infection with COVID-19
Help improve the understanding of how COVID-19 affects your health. Join the online COVID-19 Survey Study COVID INSPIRE (funded by the CDC to study the long term outcomes of infection with SARS-CoV2).
Participants: We will partner with patients to collaboratively use digital tools that generate knowledge rapidly and produce actionable insights to combat the pandemic.
You will be asked to enroll at one of the following sites near you: University of Washington, Rush in Chicago, Yale, UCSF, UCLA, UT Southwestern, UT Houston, and Thomas Jefferson.
Your participation will take less than 30-minutes, once every three months, for 18-months. You will receive $100 to participate.
Un estudio para comprender los resultados a largo plazo de la infección por COVID-19
Ayude a comprender mejor cómo el COVID-19 afecta su salud. Únase al estudio de la encuesta COVID-19 en línea COVID INSPIRE (financiado por los CDC para estudiar los resultados a largo plazo de la infección por SARS-CoV2).
Participantes:Nos asociaremos con los pacientes para utilizar en colaboración herramientas digitales que generen conocimientos rápidamente y produzcan percepciones procesables para combatir la pandemia.
Se le pedirá que se inscriba en uno de los siguientes sitios cerca de usted: Universidad de Washington, Rush en Chicago, Yale, UCSF, UCLA, UT Southwestern, UT Houston y Thomas Jefferson.
Su participación tomará menos de 30 minutos, una vez cada tres meses, durante 18 meses. Recibirás $ 100 para participar.
COVID Symptom Study: Predicting Long COVID Using a Smartphone App
This study asks those with COVID to track their road to recovery, and if applicable, their symptoms and experiences with Long COVID. Download the app and join today.
COVID-19 and Brain Health
Researchers at the University of Indiana and Mayo are conducting a for adults that had a positive COVID-19 test. The study asks questions about your experiences with the disease and your emotional, physical and personal responses. They want to learn about the symptoms you felt during your illness and how you are recovering. They are asking questions about COVID-19, confusion during COVID-19, and how you are thinking and feeling after COVID-19. This study is voluntary and you can choose to stop at anytime. The survey will take approximately 15-20 minutes to complete. No identifying information will be collected.
To participate, go to the survey.
A Symptom Survey/Study for Long Haulers
The Johns Hopkins Bloomberg School of Public Health is conducting research about how the COVID-19 pandemic has impacted people’s lives, especially around COVID-19 symptoms and recovery. You qualify if you have tested positive for COVID-19 or experienced COVID-19 symptoms.
The number and severity of persistent symptoms associated with COVID-19 Convalescence/Recovery
An NIH Study. People who get COVID-19 have a wide range of symptoms. They also recover from COVID-19 in different ways. In this study, researchers will use survey data to describe the different ways people experience and recover from COVID-19. They will also use the data to help create future studies to understand why some people do not fully recover. People ages 18 and older who have recovered or are recovering from COVID-19 in the last 6 months and can give documentation of a positive COVID-19 or antibody test, or had a clinical diagnosis of COVID with a negative test. Participants will take part in telephone interviews and online surveys. They will provide their COVID-19 test results and medical records.
Principal Investigator: Avindra Nath, M.D.
To participate, email nindspostcovid19@ninds.nih.gov
A Symptom Survey for those COVID Survivors experiencing autonomic dysfunction.
The autonomic nervous system controls involuntary or unconscious acts in the body such as heart rate, breathing, rashes, vision, pain & digestion. If it has been suggested that you may be developing POTS, this survey is for you, however any COVID patient or Survivor may participate.
A research study on symptoms experienced after a COVID-19 infection in order to further understand how the illness caused by COVID-19 evolves over time. In this study, you will be asked to fill out a brief online survey regarding your general health as well as symptoms that may have appeared after your COVID-19 illness began. We will repeat this survey every three months for one year to assess change over time. Health information will include history of COVID exposure, pre-existing conditions, medications, and continued symptoms, including those of autonomic dysfunction.
The survey is being conducted by Dr. Mitchell Miglis,
Stanford University Department of Neurology
Columbia University Study on Persistent Gastrointestinal Symptoms After COVID-19
Dr. John Blackett, a gastroenterologist and student in public health at Columbia University is studying how often and how severely patients have persistent gastrointestinal symptoms (such as stomach pain, diarrhea, nausea and vomiting) after COVID-19 infection. Diagnosed COVID-19 patients are needed to participate in an anonymous, IRB approved, online survey evaluating these symptoms before, during, and after COVID-19 infection. This study may help increase the understanding regarding what types of gastrointestinal symptoms are most common after COVID-19 and could potentially lead to future research exploring treatment options for affected patients.
COVID Vaccine Studies
Studies are taking place around the US to test vaccines in development against COVID-19. These include phase 3 studies of Moderna’s mRNA-1273 and AstraZeneca’s AZD1222. For more information see: https://coronaviruspreventionnetwork.org/.
For locations for the mRNA study, see; https://www.modernatx.com/cove-study (updated regularly). Additional sites not yet listed are Rutger’s (NJ) and St Louis (MO).
Globally Distributed Open Research and Education and New Mexico State University study to explore the lived experiences of persons affected by COVID-19 with a focus on people of color
This study explores the experiences of people who have been affected by COVID-19. Although all races and ethnicities are invited, this is a special call for people from Black, Asian and minority ethnic backgrounds and people of color (African American, Black British, Latinx/Hispanic, Asian, Black other, African, Arab, Natives and First Nations (of USA and Canada), Mixed (multi racial /ethnic groups), Caribbean, Pacific Islanders, Aboriginal and Torres Strait Islanders , Eastern European (residing in the UK) and Other ethnic minority groups (not listed above))
Do you reside in a developed country?
Have you been tested positive or suspected for Covid-19/coronavirus?
Do you identify as one of the above races/ethnicities?
Have you been clinically diagnosed with Covid-19?
Do you have any family or relative that was tested positive, suspected for Covid-19/coronavirus or clinically diagnosed with this virus?
Have you cared for someone who has tested positive/suspected for Covid-19/coronavirus or clinically diagnosed with this virus?
If you answer YES to any of these questions, and would like to take part in the study, please contact COVID19research@igdore.org OR michelle.king- okoye@igdore.org. You will be asked to meet online (via Skype, Zoom or Whatsapp video) with one researcher for an interview, which will last about an hour. You will be asked to share your story or to share your experiences of a family member who has been diagnosed with Covid-19 infection or suspected of this. Your details will not be shared and information will be kept confidential. All information gathered in this study will be discussed with policy makers, Government officials and healthcare providers to improve health services and to help them make decisions towards providing the right support for individuals, families and communities affected by Covid-19.
A Prospective "Universal" Observational Database for COVID-19
Hackensack Meridian Health is trying to come up with a descriptive, observational database for individuals who have caught the virus. Using software they created named EPIC, they plan on collecting data regarding the demographic, diagnostic, treatment and outcome data of those who have had the virus. Though the system is in lieu with patient-doctor confidentiality and follows HIPAA guidelines, participants will have to reveal data regarding their medical history and their experience. Anyone who suspects that they had the virus or who was diagnosed with it is eligible.
Contact: brittany.Sinclaire@HackensackMeridian.org OR urszula.Bednarz@HackensackMeridian.org
University of Michigan: Help others by sharing your COVID-19 story!
Doctors and researchers from the University of Michigan want to hear your stories of care and recovery throughout your journey with COVID-19. With your voice, they will be developing resources for patients and those caring for them that better support patient recovery from home. The HEART (Health Enhanced by Adjusting and Recovering Together) Project [HUM00158390] knows family, friends, and community are so important during recovery, which is why we are seeking input from two perspectives:
(1) Adults in the U.S. who were hospitalized with COVID-19 but are now recovering from home
(2) Adults in the U.S. who were caring for someone recovering from home after being hospitalized with COVID-19
Make your voice heard; share your COVID-19 story today! Visit https://heart.isr.umich.edu/ or email heartstories@umich.edu to learn more.
COVID and Pregnancy Study
The HOPE COVID-19 Study (Healthy Outcomes of Pregnancy for Everyone) is a study conducted by University of California, San Francisco that is investigating how the virus that causes COVID-19, and pandemic-related stress and hardship are affecting pregnant women, birthing persons, and infants.
The Study Team at UCSF is investigating whether the virus and associated factors, like stress and social distancing, might affect a woman's or birthing person's risk for adverse pregnancy outcomes and it might affect newborn and infant health.
Learning more about how the pandemic is affecting low-income and Black and Brown women and birthing persons who are already at increased risk for adverse pregnancy and infant outcomes is of special importance to the research team. The team is looking at how perceived discrimination and systematic racism may be impacting infection with the COVID-19 related virus and associated stress and outcome patterns.
To participate, a person must be pregnant, 18 years of age or older, comfortable downloading and using mobile phone apps, and comfortable reading and writing in English. (Spanish to follow in early 2021.)
Enroll: Survey Only Cohort
A more detailed Survey + Testing Cohort will follow later in 2020, for interested pregnant women, living in San Francisco, Marin, Sonoma, Napa, Solano, Contra Costa, Alameda, Santa Clara or San Mateo counties. Email HOPE_COVID19@UCSF.edu to be contacted when enrollment starts.
Assessing the Safety of Pregnancy In the CoRonavirus (Covid-19) pandEmic (ASPIRE) (San Francisco)
This research is focused on assessing how the coronavirus infection may impact the growth and development of fetuses. The researchers require adult participants who are 4-10 weeks pregnant. Participants of the study will have to submit symptom tracking report questionnaires online, complete questionnaires about health during pregnancy and after delivery, and collect finger-stick blood samples from home at different points of the pregnancy. It is a long study with a follow up period of 20 months. The results of the study will help develop strategies to protect the safety of pregnant women and babies amidst the pandemic.
Contact: heather.huddleston@ucsf.edu or ASPIRE@uscf.edu
Registry to Study Factors That May Impact COVID-19 Occurrence and Severity
This study, lasting 3 months, is meant to collect data from individuals who may be exposed to the virus in order to understand risk-factors, symptoms and treatments for the illness. The participants will be expected to complete an initial baseline survey reporting their demographics, relevant medical history, symptoms, use of prescription and non-prescription medications (prophylactic and curative) as well as use of supplements (e.g., vitamins, minerals, herbals) and other factors, such as extent of isolation. During month 1, participants will be expected to complete a symptom diary. During months 2 and 3, follow ups will happen only twice a month.
Contact information: barbara.arone@iqvia.com
MAYO Early Prediction of Aggressive COVID-19 Progression and Hospitalization Study Using Remote Monitoring Devices
A hallmark of COVID-19 is its ability to get worse quickly and aggressively. While the 10 to 12 days after a positive COVID-19 test are when many patients are hospitalized, researchers do not understand what changes occur early in the disease and how they may predict hospitalization later. Additionally, while many patients recover within 14 days of symptom onset, the illness can take more than 25 days to resolve for some patients.
This study uses remote monitoring devices to help researchers understand how COVID-19 progresses and resolves. The goal of the study is to gather vital sign and symptom data that will help the research team develop and verify an algorithm that predicts when an infection may suddenly or aggressively get worse in the future. The study team hopes that such an algorithm will allow for earlier treatment, identification of potential cutting-edge treatment opportunities or trials, and advanced planning of hospital resources, all of which are critical to minimizing disease impact and optimizing the clinical care of patients with COVID-19.
You are eligible to participate in this study if you:
· Are over the age of 18
· Have received a positive test for COVID-19 within the past 48 hours and can provide documentation of the test
· Are comfortable using and willing to interact with a tablet-based interface on a daily basis
Info: https://www.mayo.edu/research/remote-monitoring-covid19-symptoms/people-with-covid19
NIH Investigation of the B- and T-cell Immune Response
The purpose of this study is to examine how immune cells respond to COVID-19 infection over a long term period (up to 2 years). People who get infected with COVID-19 have an unpredictable risk to worsen and die. This makes it hard to decide who can quarantine at home and who should be treated at a hospital. Researchers think the risk may be related to how a person’s B and T cells respond to the virus. B and T cells are the major components of a person’s immune response. B and T cells responding to the virus with a favorable pattern may lead to recovery.
The study is seeking:
Adults ages 18 and older who have a confirmed or suspected COVID-19 infection or had COVID-19 in the past AND, healthy participants with no suspected COVID-19 infection Participants will be screened with medical record review. Participants will be tested with a research assay to determine who was infected with COVID-19 and who was not. This test will be used to understand research results, not to advise patients. Participants may give multiple blood samples at NIH or at their local doctor’s office or lab. Participants will be contacted by phone or email every 2 months for up to 2 years.
Interested participants should contact Monica E Epstein: monica.epstein@nih.gov
Once accepted into the study, test kits may be sent to the participants and sent back to the study via FedEx. For more information see: https://clinicaltrials.gov/ct2/show/NCT04362865
Stanford University: COVID-19 Wearables Tracking Study
Stanford University is conducting a study using wearable devices, like Fitbit and Apple Watch, to track infectious diseases like COVID-19. With the collected data they hope to be able to predict the onset even before any symptoms start.
They are currently looking for people who own a wearable device and:
Have had a confirmed or suspected case of COVID-19, or
Have been exposed to somebody who has known or suspected COVID-19, or
Are at higher risk of exposure (like healthcare workers or grocery store workers).
This is an easy and non-invasive way to help scientists understand COVID-19.
Info: https://innovations.stanford.edu/wearables
EPA’s Antibodies in Saliva Study
The purpose of this research study is to develop a non-invasive test for population surveillance of COVID-19. The study involves measuring antibodies in saliva samples. These antibodies are naturally produced by the human body in response to SARS-CoV-2 infection. The study is conducted by the U.S. Environmental Protection Agency (EPA).
You may be able to take part in the study if you are:
▪ An adult of at least 18 years of age ▪ Are an American resident ▪ Have been informed by a healthcare professional that you had a positive test result for SARS-CoV-2, the virus which causes COVID-19 ▪ Your positive test result must have occurred in the previous 2 months You will be asked to: ▪ Complete a very simple questionnaire ▪ Collect 2 saliva samples at home and return them by pre-paid mail to EPA ▪ You may also be asked to participate in a follow-up study which involves collection of three more saliva samples over one year to see how antibody responses change over time.
You will receive $25 for each sample collection event for this study. Office hours are Monday - Friday from 8 am to 5 pm ET.
To enroll or for more information, call: 919-966-0604 (local), 1-888-279-9353 (toll free)
More information at: https://epastudies.org/
Enable BioScience: Antibody Test Validation Study
Enable Biosciences is following FDA guidance to validate their ultrasensitive antibody assay for use in clinics and in the home. They need biological samples to further validate their technology so they can get the test out to the people who need it most. This is the "Did I Have it?" test: not the "Do I Currently Have It?"
They are currently recruiting 2 types of individuals:
1. PCR-confirmed positives (with documentation of their test results. (Anywhere in the United States.)
2. Individuals with NO symptoms (Cough, shortness of breath [SOB], fever, chills, muscle pain, sore throat, or loss of smell or taste) going back to January 2020. (Prioritizing individuals local to the Bay Area.)
Results will be provided to participants as a courtesy via a discussion with the physician overseeing the study. Please allow 1-3 weeks from sample submission to allow for lab analysis. Please note that this is a validation research study for an investigational assay and *not* a clinical service. https://www.enablebiosciences.com/sars-cov-2-donors
ImmuneRACE T-Cell Study Immune Response Study -
Have you had a confirmed diagnosis of COVID-19 or were you exposed to someone with COVID-19 and want to be part of this study? If you are between the ages of 18-89 and live in one of the metro areas listed below, you may be eligible : (We are not able to return individual test results.)
Participate: immunerace.adaptivebiotech.com/how-to-participate/
Locations:
Atlanta, GA Baltimore, MD Baton Rouge, LA Boston, MA Chicago, IL
Dallas, TX Hartford, CT Houston, TX Indianapolis, IN Kansas City, KS
Los Angeles, CA Miami, FL Nashville, TN New Brunswick, NJ New York, NY Philadelphia, PA Phoenix, AZ Richmond, VA Sacramento, CA San Diego, CA
San Francisco, CA Seattle, WA Tampa, FL Tyler, TX Washington, DC
Wayne State University Survey
A clinical researcher at Wayne State University in Detroit developed this survey with the input of ER physicians and is requesting information about COVID-19 symptoms and experiences. To participate you must be at least 18 years old and must have tested positive for COVID-19 or have been diagnosed/assessed as having COVID-19 by a physician or medical professional (even with no test done). If you are interested in participating, see the link below.
https://waynestate.az1.qualtrics.com/jfe/form/SV_2aZXGdtLMcxDMhL
Opu Labs - Photos of SKIN CONDITIONS needed
Opu Labs is developing a analysis method and database of skin conditions related to COVID-19 and is requesting images of skin conditions from people with COVID-19 to help with their analysis. 20% of COVID-19 infected persons have some type of identifiable skin condition. By recognizing these types of skin conditions through image analysis, Opu AI can help identify infected persons beyond what infrared devices and other scanning procedures are currently doing. Once complete, their tool will assist symptom tracker developers, first line workers and public venue staff to identify potential COVID-19 cases. Ops Labs needs help to collect more images and data to train Opu AI.
Read more and submit your images at: https://www.opulabs.com/opu-labs-announces-covid-19-viral-detection-research-initiative/
Biological Specialty Company
BSC is seeking donors of blood or plasma from those who have an ACTIVE COVID infection - as well as people who are recovered. They have mobile units that will come to you.
Register - Recovered: www.biospecialty.com/covid-19-recovered
Donor Requirements: Eligible to donate at donor center (be at least 28 days post resolution of symptoms after a diagnosis of COVID-19 or 28 days after the last possible close contact exposure to a person with COVID-19), be able to provide a copy of a positive PCR test (saliva/swab collection), be willing to donate whole blood or plasma through the apheresis process, and have a photo ID and be able to provide your social security number or proof of citizenship. You must be at least 18 years old. You must weight at least 110 lbs. You must disclose if you have ever been diagnosed with Hepatitis C and/or HIV. Be pre-screened to determine eligibility.
Tufts University COVID-19 Convalescent Patient Registry
This national registry will connect you to research studies in your area or from around the country conducted by researchers at major academic institutions, non-governmental organizations and biopharmaceutical companies.
Tufts Clinical Translational Science Institute is hosting a research registry under the direction of Dr. Andreas Klein, MD collecting information on persons who have recovered following an infection with the SARS-CoV-2 virus that causes the illness called COVID-19.
Participants must be adults living in the United States who believe they have had COVID-19 (either through self diagnosis, medical diagnosis or testing). If you choose to register, you will need to complete an initial survey regarding your COVID-19 illness experience and how likely you would be to want to take part in certain types of research activities.
Register: http://C19Registry.org
Survey about Loss of Taste and Smell
Researchers at Virginia Commonwealth University have released a survey for people who have experienced a change in their sense of smell or taste since January or have been diagnosed with COVID-19. It will allow researchers, led by principal investigator Evan Reiter, M.D., professor in the Department of Otolaryngology - Head and Neck Surgery at the VCU School of Medicine, to study the potential link between an individual’s COVID-19 diagnosis and a loss of their sense of smell, called anosmia, or a loss of their sense of taste, called ageusia.
IF YOU HAVE EXPERIENCED changes to their sense of smell or taste this year or who have had a COVID-19 diagnosis to access and participate in the survey. https://redcap.vcu.edu/surveys/?s=YHRYAFDXTW
AAD: Survey on Skin Rash and COVID -19 (Physicians Only)
American Academy of Dermatology. THIS IS FOR PHYSICIANS ONLY. If you had these conditions, please share with your doctor and ask them to fill it in.
This survey is for all health care professionals taking care of (a) COVID-19 patients who develop dermatologic manifestations, or (b) dermatology patients with an existing condition who then develop COVID-19.
COVID-19 has been associated with a wide range of symptoms. Reports from Italy and Thailand indicate that skin rash might be another symptom of COVID-19. Skin rash at the beginning of disease onset is more common. No one particular skin rash has been observed and skin rash has not been associated with severity or prognosis of the disease.
Sanguine Blood Centers
Sanguine is a blood center matching service working with a number of studies to connect potential plasma donors to research. If they have a match, they will send a mobile service to you to take your plasma donation. Sign up at: https://patients.sanguinebio.com/coronavirus-covid-19-update/
Grifols Plasma Collection
Grifols is one of the companies partnered with the US FDA that is developing a hyperimmune globulin product, a concentration of antibodies, that will be tested and used for treatment of COVID-19. They are in need of plasma donations from people who have fully recovered from COVID-19 and whose blood contains antibodies that can fight the novel coronavirus.
Requirements:
weigh at least 110 pounds
be in good general health
be 18-69 years old
National Call Center: (866) END-CV19
COVID-19 Family Support Survey
STUDY BASICS
Are you the parent of a child age 0-17, or are you an expectant parent (pregnant or the partner of someone who is pregnant)? If so, you may be able to participate in a research study to help better understand how parents and adult caregivers are dealing with the challenges caused by the COVID-19 (Coronavirus) pandemic.
https://pittplusme.org/studyarms/publicdetails?guid=1b96a218-92a9-44c6-8a8d-92ec97a888ce
ColCorona Clinical Trial on Colchicine
The ColCorona Clinical Trial seeks to assess the medication Colchicine, an oral anti-inflammatory used to treat gout and pericarditis. Colchicine has been used successfully for decades to reduce inflammation and recently in the COLCOT study was shown to significantly reduce cardiovascular events when taken after a heart attack. It has a well established safety profile. It is being studied for its potential ability to keep high-risk COVID-19 patients from progressing into critical stages. A prior small study in Greece is reported to have been effective in preventing cytokine induced pneumonia. https://www.sciencedirect.com/science/article/pii/S1109966620300610
The experimental treatment, colchicine, is to be sent to patients' homes hours after COVID-19 diagnosis. It is hoped colchicine will prevent cytokine storm, where the immune system dangerously overreacts. Teams at UC San Francisco (UCSF) and New York University School of Medicine will send the anti-inflammatory drug colchicine to people's homes within 48 hours of them testing positive for coronavirus. Participants can stay at home during the study. To take part, participants must be aged at least 40 and be at risk of suffering COVID-19 complications, for instance by having diabetes, heart disease, chronic pulmonary disease or being aged 70 or above. They must also live in the geographic region of the study site so they can be sent the drugs. Some volunteers will be randomly assigned colchicine, while others will be given the placebo as the control group.
For more information or to take part in the trial to determine whether a short-term treatment with a medication reduces the risk of death and lung complications related to COVID-19. Participants must have a COVID-19 positive diagnosis, agree to the terms of the trial and follow up appointments, be over 40, not hospitalized and not be pregnant or breastfeeding. More details are available at: https://en.colcorona.net/ and https://www.smartpatients.com/trials/NCT04322682.
To participate, contact your healthcare professional or call 1-877-536-6837
The trial is presently available in New York City Tri-State area, San Francisco, Los Angeles, Miami, Houston, Dallas, Phoenix, Yuma, Jacksonville, Rochester and Bakersfield, Madrid (Spain), Montreal (QC), Ontario and British Columbia, Cape Town (SA).
Argentina
COVID-19 Sequelae: Treatment and Monitoring. A Dietary Supplement Based on Sea Urchin Eggs With Echinochrome A (Buenos Aires)
The aim of this study is to assess the efficacy and efficiency of a nutraceutical from sea urchin eggs with Echinochrome A in the inflammation of tissues in subjects with long COVID syndrome.
Inclusion Criteria:
Positive diagnosis of COVID-19 in at least the last 12 weeks
Diagnosis of COVID Persistent, COVID sequalea, Long COVID
Adult men or non-pregnant adult women between the ages of 18 and 60.
The patient (or legally authorized representative) provides your informed consent before initiating any study procedure.
The patient (or legally authorized representative) understands and agrees comply with the planned study procedures. 6. Agreement not to participate in another trial ofintervention for the treatment of COVID-19 until day 60 after the start of the trial.
Exclusion Criteria:
1. Patients without persistent COVID symptoms. 2. Patients unable to give informed consent. 3. Patients without a positive result for COVID-19. 4. Pregnancy or lactation. 5. In the doctor's opinion, the patient with advanced organ dysfunction that would not make participation appropriate.
Contact: Fernando Saldarini, MD | +54 9 11 37030712 | fernando.saldarini@gmail.com
Valeria Brichetti, MD | +54 1153255656 | neumobrichetti@gmail.com
Australia
Statin TReatment for COVID-19 to Optimise NeuroloGical recovERy (STRONGER) (Sydney)
The STRONGER study is an international, investigator initiated and conducted, pragmatic clinical trial to determine whether 40mg atorvastatin daily can improve neurocognitive function in adults with long COVID neurological symptoms.
The objective is to determine effectiveness of treatment with 40mg atorvastatin over 18 months on attenuating cognitive decline and neuroinflammatory biomarkers in adults with long COVID neurological symptoms. The study design is a prospective, randomised, open-label, blinded endpoint (PROBE) study of atorvastatin 40mg on top of standard care, in patients with long COVID neurological symptoms.
Inclusion Criteria:
Age ≥18 years
History of COVID-19 that is confirmed by a positive polymerase-chain-reaction (PCR) test
Any ongoing neurological symptoms as a result of COVID-19 (e.g. problems with memory, concentration, sleep disturbance and fatigue) that are identified through administration of the checklist of symptoms on the Somatic and Psychological Health Report (SPHERE) questionnaire, or reported loss of smell (anosmia)
Able to fully participate in all procedures, including cognitive assessments
Able and willing to provide written informed consent
Exclusion Criteria:
Evidence of dementia and/or significant cognitive impairment on screening (i.e. Blind Montreal Cognitive Assessment [MoCA] score <19/22)
Severe co-morbid medical or psychiatric condition that prevents participation
History of traumatic brain injury with loss of consciousness (>30 mins) within the last 2 years
Ongoing long-term use for a clear indication (e.g. secondary cardiovascular prevention in high-risk individuals) or any contraindication (e.g. previous adverse reaction) of statin use
Evidence of severe or significant liver disease, defined as any of the following: acute viral hepatitis; chronic active hepatitis; chronic active hepatitis; cirrhosis; or elevated biochemical function markers i.e. ALT or AST >3x the ULN or eGFR <30mL/min/1.73m2
Creatine kinase (CK) levels > 2x upper limit of normal (ULN)
Female of child-bearing potential that is unable or unwilling to use reliable method of contraception, breastfeeding, or planning a pregnancy
For a sub-group of participants undergoing MRI - any contraindication to MRI due to metallic body parts or claustrophobia
Medical history of a disorder that might, in the opinion of the attending clinician, put the participant at significant risk if they were to participate in the trial
Contact: Craig Anderson, MD | +61 2 8052 4521 | canderson@georgeinstitute.org.au
Austria
Post-COVID-19 Outpatient Care and Biomarkers (POSTCOV) (Vienna)
The aims of this case-control, non-randomized study including patients with post-COVID-19 persisting symptoms are 1) to establish the large blood biobank, 2) to examine levels of circulating inflammatory biomarkers and different classes of non-coding RNAs (ncRNA), such as selected circRNAs and miRNAs, in plasma and serum samples collected from patients with post- COVID-19, 3) to test the levels of cfDNA in plasma and serum, 4) to define correlation between ncRNAs and cf-DNA with persistent clinical symptoms, and type of symptoms, and 5) to investigate diagnostic and prognostic performances of these circulating biomarkers.
Inclusion Criteria:
For post-COVID patient group:
Age≥18 to 90years
Proven infection by SARS-CoV2, at least 3 weeks after recovery from the infection
Signed informed consent For HFrEF patient group:
For vaccinated healthy volunteer control group:
Full vaccination against SARS-CoV2 at least 3 weeks before inclusion in the study
Signed informed consent
Exclusion Criteria:
non-willingness to participate or withdrawal of informed consent
Clinically confirmed HFrEF (EF <40%)
participation in any SARS-CoV-2 medical treatment trial
pregnancy
Contact: Mariann Gyöngyösi, MD PhD | +4314040046140 | mariann.gyongyosi@meduniwien.ac.at
Christian Hengstenberg, MD PhD | +4314040046140 | christian.hengstenberg@meduniwien.ac.at
Belgium
Long-term Effects of SARS-CoV-2 on the Central Nervous System and One-year Follow-up of "Long COVID-19" Patients (Brussels)
The primary objective of this study is to determine the different types of neurological dysfunction and clinical manifestations of the "long COVID-19" syndrome and to correlate them to abnormalities/signs on cerebral perfusion scintigraphy. Furthermore, the investigators aim to determine and validate a specific imaging biomarker of post-COVID-19 encephalopathy.
The secondary objective of this study is to determine the best therapeutic modality to treat and improve prognosis of patients with "long COVID-19" syndrome with defined central nervous system impairment.
Inclusion Criteria:
Age ≥ 18 years;
Physically and mentally able to fill out questionnaires;
Suspicion and/or confirmation of COVID-19 infection, managed on an out- or inpatient (COVID-19 ward or ICU) basis;
Residual symptoms at 8 weeks or more after initial SARS-CoV-2 infection.
Exclusion Criteria:
Diagnosed with a neurological syndrome e.g. Parkinson disease, Alzheimer disease, … before SARS-CoV-2 infection;
Known Dementia or mild cognitive impairment before SARS-CoV-2.
Contact: Marie Dominique Gazagnes | 3224773462 | MarieDominique.GAZAGNES@chu-brugmann.be
Tatiana Besse-Hammer | 3224773312 | tatiana.besse-hammer@chu-brugmann.be
Nutrition and LOComotoric Rehabilitation in Long COVID-19 (UNLOCK) (Brussels)
The aim of this pilot-study is to learn more about the complications that long COVID patients continue to experience after their infection, how this affects their lives to a greater or lesser extent, and whether a patient-tailored physical rehabilitation programme combined with individualized nutritional therapy leads to a faster recovery compared to a classic exercise program with a physiotherapist.
Inclusion Criteria:
Able to understand and sign written consent in Dutch, French or English
Laboratory (PCR and/or serology) confirmed infection with SARS-CoV-2 less than 12 months ago
Persisting functional difficulties and symptoms: exercise intolerance and/or fatigue and/or muscle pain beyond 12 weeks beside other COVID-related symptoms (e.g., loss of taste and/or smell)
Patient affiliated to a social security system
Exclusion Criteria:
Patients unable to comprehend oral and/or written instructions, questionnaires in English, French or Dutch.
Patient currently suffers from any other disease beside long COVID that could explain the symptoms (e.g., fibromyalgia, Sjögren disease, severe anaemia...)
Patient is unable to undergo a rehabilitation programme due to comorbidities (e.g., major cardiovascular disease such as myocarditis or severe dementia), as decided on by the medical study team members.
Patient currently benefiting from physiotherapy sessions with focus on motor and/or respiratory therapy for COVID-19 or any other unrelated disease
Patients with metabolic disorders or severe gastro-intestinal conditions (e.g. short bowel syndrome)
Contact: Berenice Jimenez Garcia, MSc | 0032 2 474 9624 | Berenice.JimenezGarcia@uzbrussel.be
Lynn Leemans, PhD | 0032 2 474 9624 | Lynn.Leemans@vub.be
Long-COVID: Treatment of Cognitive Difficulties (COV-COG) (Antwerp & Liège)
The purpose of this study is to explore the potential effectiveness of two common low-dose interventions, one targeting cognitive difficulties and the other targeting affective difficulties on quality of life and cognition in people suffering from long-COVID with cognitive complaints.
Inclusion Criteria:
Subjects able to understand the information and consent forms;
Medically stable and at least 3 months after positive PCR for Covid-19;
Self-reported sufficiently good physical condition to attend the appointment;
No major hearing or vision disorders;
Cognitive complaints that place the person in the top 20% of dissatisfied functioning on the BRIEF or MMQ questionnaires;
Poor objective performance supported by a score below the 20th percentile on one task of the cognitive battery.
Exclusion Criteria:
Any chronic or remote neurological disorder (i.e. stroke, head trauma, epilepsy, tumor);
Cognitive impairment (minor or major neurocognitive disorder; intellectual disability) preexisting to the Covid-19 episode;
Acute brain injury or acute encephalopathy from another aetiology than covid (e.g., sepsis, liver or renal failure, alcohol or drug withdrawal, drug toxicity);
Documented preexisting history of psychiatric illness, including substance abuse; Open-heart cardiac surgery or cardiac arrest during the last 6 months;
Current hospitalization;
Current revalidation care with cognitive treatment
Contact: Carmen Cabello, MD | +32 4 3663359 | C.Cabello@uliege.be
Alexia Lesoinne, MD | +32 4 3662989 | Alexia.Lesoinne@uliege.be
Pulmonary Rehabilitation for Long COVID (Post COVID-19 Condition) (PuRe COVID) (Antwerp)
In the PuRe COVID study (a randomized, controlled, multicenter, pragmatic trial) the investigators aim to assess the effect of a pulmonary rehabilitation program in primary care on exercise capacity (6MWT) and daily life physical activity in patients with long COVID.
Inclusion Criteria:
Adult patients with status post COVID-19 (positive COVID-19 PCR or an official pharmacy performed antigen test ≥6 weeks ago)
Persistent COVID related symptoms that were not present pre-COVID-19 or were less severe pre-COVID.
Symptomatic: quantified by dyspnea on exertion, loss of energy, fatigue or sleep impairment based upon the score of four questionnaires:
COPD Assessment Test (CAT) ≥10, and/or
modified Medical Research Council dyspnea scale (mMRC) ≥2, and/or
CIS-fatigue ≥36, and/or
post-COVID-19 Functional Status (PCFS) ≥2.
Exclusion Criteria:
Patients with known or self-reported cognitive, hearing, visual, neurological or musculoskeletal conditions that make it impossible to participate in pulmonary rehabilitation.
Prior physiotherapy for long COVID if:
patients who have completed ≥9 sessions of physiotherapy in total for long COVID.
patients who completed any physiotherapy session in the previous 12 weeks for long COVID (primary care or hospital based; pulmonary or non-pulmonary).
Patients with predominantly neurological disorders impacting respiratory function will not be eligible for the study.
Patients that are not able to give informed consent or not able to complete questionnaires.
Contact: Tess Volckaerts, Master | 00328212395 | tess.volckaerts@uza.be
Thérèse Lapperre, Prof. | 003238212153 | therese.lapperre@uza.be
Brazil
EEG as Predictor of HD-tDCS Effectiveness in Long COVID-19 (Paraiba)
Recent investigations suggest that people who were infected by COVID-19 often develop physical disabilities (i.e. pain, fatigue) and neurological complications after hospital discharge. Many therapeutic approaches such as transcranial direct current stimulation (tDCS) have been proposed to minimize functional and structural impairments. Electroencephalogram (EEG) has been used in this population to assess electrophysiological changes in the brain. However, evidences about EEG utilization as efficacy predictor of tDCS in COVID-19 people rest inconclusive.Our objective is to evaluate EEG as neurobiological predictor marker of tDCS efficacy on fatigue, pain, quality of life, self-efficacy and functional capacity in the chronic phase of COVID-19.
Patients who had a medical diagnosis of COVID-19, clinically stable, able to respond to simple commands, able to walk for six minutes and who sign study consent form will be enrolled. Those who present associated neurological diseases, pregnant, users of psychoactive drugs, patients who have metallic implants, electronic devices, pacemakers, or epileptic patients will be excluded.
Contact: Suellen Andrade, PhD | 986046032 | suellenandrade@gmail.com
Kelly Santana | 11 910403928 | kjs.fisio@gmail.com
Osteopathy and Physiotherapy Compared to Physiotherapy Alone on Fatigue and Functional Status in Long COVID (Rio de Janeiro)
Fatigue is among the most common symptoms of the wide spectrum reported as the long-term effects of coronavirus (long COVID). This study aims to compare the effectiveness of osteopathic manipulative treatment (OMT) combined with physiotherapy treatment (PT) compared to PT alone on fatigue and functional limitations after two months post randomization in adults with long COVID.
Inclusion Criteria:
Individuals with long COVID-19 infection, for at least 18 months, referred for rehabilitation; report of fatigue as major symptom after acute COVID-19 infection;
Ability to understand Portuguese well enough to be able to fill in the questionnaires.
Exclusion Criteria:
Suspected or diagnosed chronic and/or neurological diseases;
Pre-existing, chronic diseases affecting the musculoskeletal system
Contact: Arthur Sá Ferreira, PhD | 5521999151800 | arthur_sf@icloud.com
Ana Paula An Ferreira, PhD | 5521991134044 | osteoferreira@gmail.com
Post-COVID Brasil Study 1 (Porto Alegre)
The present prospective cohort study aims to assess factors associated with one-year health-related quality of life and physical, cognitive and mental health outcomes among adult survivors of hospitalization for COVID-19. Adult patients requiring hospitalization due to COVID-19 disease will be followed through structured and centralized telephone interviews performed at 3, 6, 9 and 12 months after enrollment.
Inclusion Criteria:
Age ≥18 years;
Symptomatic COVID-19 disease within the last 14 days;
Positive polymerase chain reaction (PCR) test for SARS-CoV-2 within the last 14 days;
Need of hospitalization (duration ≥ 48 hours).
Exclusion Criteria:
Severe comorbidity with life expectancy less than 3 months;
Death during hospitalization;
Absence of telephone contact;
Absence of proxy for patients with communication difficulties;
Refusal or withdrawal of agreement to participate;
Previous enrollment in the study.
Contact: Geraldine Trott, PhD | +5551994407117 | geraldine.trott@hmv.org.br
Canada
Manitoba
Tele-monitoring of COVID-19 Survivors for Long-Term Impacts (Winnipeg)
To confront the COVID-19 pandemic, hospitals need to maximize bed availability and minimize the duration of patients' stay as much as possible. Given the constraints, physicians are neither able to investigate the long-term effects of COVID-19 nor able to optimize extended treatments beyond the hospital. Physicians also do not have time to keep patients mobile and lucid during their hospital stays, resulting in longer recovery periods and further complications for patients.
The investigators propose the development of a tele-monitoring solution for the long-term monitoring of COVID-19 survivors. Such a solution will help save significant healthcare costs by reducing the number of plausible future hospitalizations due to patient complications, providing valuable insights to various stakeholders from doctors to policymakers on the long-term effects of COVID-19, and improving patient care and treatment.
Inclusion Criteria:
Age >18 years,
MoCA > 15
Clinically diagnosed with COVID-19 and have had symptoms for a minimum of 5 days
Must speak and understand English
Must have wifi Internet and an smart phone
Contact: Zahra Moussavi, Ph.D. | (204) 474- 7023 | Zahra.Moussavi@Umanitoba.ca
Ontario
Investigating Development of Autoimmunity in Post-Acute COVID-19 Syndrome (PACS) (Hamilton)
It is now apparent that a significant proportion (15%) of patients who recover from COVID-19 continue experiencing symptoms such as chronic fatigue, shortness of breath, joint pains, cognitive impairment ("brain fog"), etc. for several months, if not for life. This syndrome has been labeled as "long-COVID" or Post-Acute COVID-19 Syndrome (PACS) and can happen to anyone whether you're young, old, healthy, or have a chronic illness. One can get it even if the COVID-19 symptoms were mild. There is no confirmed cause as to why this happens.
However, there is data to support that inappropriate activation of the immune system by the virus may play a role. While our immune system is programmed to protect us against foreign invaders (such as viruses), in this case, it is directed against elements of our own. The net result is autoimmunity, where the immune system produces autoantibodies that cause damage to the body. This may lead to the development of chronic and serious diseases like lupus, rheumatoid arthritis, vasculitis, scleroderma, and others.
The aim of this study is to understand the exact impairment of the immune system, why these patients develop autoantibodies, characterize their impact on the clinical symptoms of PACS, and, potentially, identify ways to modify this.
Inclusion Criteria:
18 years up
Positive PCR or antibody test
12 weeks post acute Covid infection with PASC
Exclusion Criteria:
Pre-existing Auto- immune disease
Chronic/ secondary infections
Active Neoplasm
Pregnancy
Contact: Snehal Somalwar | 905-522-1155 ext 35594 | ssomalwa@stjoes.ca
"Long COVID-19" on the Human Brain (Toronto)
The goal of this study is to use advanced brain imaging to determine whether people who have been infected with COVID-19 show damage in their brain. The hope is that this information will help doctors determine what treatments should be provided to help people who are suffering from continuing mental problems after being infected with COVID-19.
Inclusion Criteria:
Persons of all races, ethnicities, genders, and sex.
18 years of age or older.
Fully vaccinated for COVID-19 with authorized vaccines in Canada.
Participants in COVID-19 groups (Group A and B) will have the following additional inclusion criteria:
Previously infected with mild-moderate COVID-19 (i.e., out-patients never hospitalized for COVID-19), as confirmed by review of clinical history.
Not currently infected with SARS-COV-2, as confirmed by COVID-19 Rapid Antigen Test (RAT).
Additionally, participants enrolled as part of the CNS-PASC group (Group A), must also:
1. Currently experience CNS-PASC symptoms, not present prior to infection, as confirmed by the "Long COVID-19 Symptom Assessment" scale.
Exclusion Criteria:
Unstable medical conditions and/or active uncontrolled autoimmune or inflammatory conditions.
Neurological conditions and/or concussion present prior to COVID-19 infection.
Substance abuse disorder (except caffeine, nicotine, and cannabis/marijuana) within 6 months of entering the study, as determined by the Structured Clinical Interview (27)
Positive urine drug screen for drugs of abuse at the screening visit.
Pregnancy (Note: Females up to age 65 must have negative urine pregnancy test at screening), or breastfeeding.
Score <32 on the Wide Range Achievement Test-III.
Receiving treatment with medications such as levetiracetam that blocks SV2a binding.
Disorders of coagulation or taking anticoagulant medication that prevents arterial line cannulation.
Pacemakers, metallic cardiac valves, magnetic material such as surgical clips, implanted electronic infusion pumps or any other conditions that would preclude the MRI scan.
Body size/weight above the limits for PET and MRI scanners.
Exceeding allowed annual radiation exposure levels for research scans of 20 mSv in the past 12 months as outlined by our PET Centre guidelines.
Having completed multiple PET scans in the past, such that participation in this study would cause participant to exceed lifetime limit (8 PET scans).
Currently receiving active treatment for cancer.
Claustrophobia.
Contact: Ariel Graff, MD, PhD | 416-535-8501 ext 34834 | ariel.graff@camh.ca
Philip Gerretsen, MD, PhD | 416-535-8501 ext 39426 | philip.gerretsen@camh.ca
Self-Management Interventions for Long-COVID (Toronto)
The purpose of this study is to investigate and compare the feasibility and efficacy of two group-based interventions (education vs. mindfulness) to help self-manage Long-COVID symptoms.
Inclusion Criteria:
Clinically diagnosed Long-COVID plus PCR positivity with and without hospitalization
3-12 months post-diagnosis of COVID-19
>2 self-reported persisting symptoms in >1 mood, cognitive and/or somatic symptom domain
Age >18
English speaking
Private access to computer/internet
Exclusion Criteria:
Acute ventilator support
Diagnosed dementia
Past/present history of psychotic illness or mania and, because of potential overlap in symptoms, diagnosis of chronic fatigue syndrome, fibromyalgia, chronic lyme disease or traumatic brain injury
Long-COVID symptom severity (i.e., physical, cognitive, emotional symptoms) at a level that would significantly interfere with attendance/adherence to the intervention protocol
Contact: Julia Rybkina, MSc | 416-597-3422 ext 7651 | julia.rybkina@uhn.ca
Nithin Jacob, MSc | 416-597-3422 | nithin.jacob@uhn.ca
The Canadian Respiratory Research Network Long COVID-19 Study (Toronto)
Preliminary studies suggest that COVID-19 causes long-term lung damage, even in young, otherwise healthy people who did not need to go to hospital or the ICU.
The researchers seek to know how common long-term lung damage after COVID-19 is, who is most affected by it and what the effects of this damage are on other important aspects of people's lives. We plan to study a large sample of people with a history of COVID-19 infection from across Canada-some who needed hospitalization but most who did not. Through online questionnaires, we will determine their respiratory symptoms, quality of life and medical history. Then we will invite them to one of our thirteen Canadian testing centres to have special, thorough breathing tests.
The researchers hypothesize that COVID-19 leaves a significant proportion of people with measurable respiratory impairment.
The information we learn about the effect of COVID-19 on the lungs will help patients and health care providers manage it better. It will also reveal how different COVID-19 variants affect the lungs. We will use this new knowledge to write a formal guide on what respiratory monitoring and testing should be done after COVID-19 infection. This will ensure that people affected by COVID-19 get the care they need to maintain their lung health
Inclusion Criteria:
Aged ≥18
Community dwelling
First occurrence of a positive PCR test for SARS-CoV-2 infection and symptomatic infection 6-12 months previously
Exclusion Criteria:
Not able to communicate with our research personnel (themselves or through a translator)
Contact: Andrea Gershon, MD, MS | 416-480-6100 ext 3619 | andrea.gershon@sunnybrook.ca
Vortioxetine for Post-Covid-19 Syndrome (Mississauga)
A randomized, double-blinded, placebo-controlled trial will be conducted to evaluate vortioxetine, an antidepressant with established pro-cognitive properties, for the treatment of cognitive deficits which develop during or after an infection consistent with COVID-19, continue for more than 12 weeks and are not explained by an alternative diagnosis (i.e., post-COVID-19 syndrome). Participants will receive vortioxetine (10-20 mg) or placebo for 8 weeks. Changes in cognitive functioning from baseline to endpoint (week 8) will be assessed via the Digit Symbol Substitution Test (DSST).
Inclusion Criteria:
Age 18-65
Meets NICE-defined post-COVID-19 syndrome (NICE Definition: Signs and symptoms that develop during or after an infection consistent with COVID-19, continue for more than 12 weeks and are not explained by an alternative diagnosis). To ensure the above criteria is met, participants will only be included in the study if they meet all eligibility criteria more than 12 weeks from their confirmed and documented positive polymerase chain reaction (PCR) SARS-CoV-2 test.)
Documented history of SARS-CoV-2 infection with typical symptoms, and requiring positive SARS-CoV-2 test (PCR, antigen or antibody) at some point during the course or (in the case of antibodies) also after the acute course of illness
Subjective cognitive complaints as detected by the Perceived Deficits Questionnaire (PDQ)-5
Ability to provide written informed consent
Exclusion Criteria:
Current symptoms are fully explained by major depressive disorder or bipolar disorder.
Pre-existing conditions that may cause cognitive impairment, or symptoms similar to those seen in post-COVID-19 syndrome (e.g., major neurocognitive disorder, schizophrenia, chronic fatigue syndrome [CFS]/ encephalitis meningitis [EM]), as assessed by Mini International Neuropsychiatric Interview (MINI) 7.0.2.
Inability to follow study procedures.
Known intolerance to vortioxetine and/or prior trial of vortioxetine with demonstrated inefficacy.
Not currently taking any other antidepressant in the past 4 weeks.
Current alcohol or substance use disorder.
Inability to provide consent.
Current alcohol and/or substance use disorder as confirmed by the M.I.N.I 7.0.2
Presence of comorbid psychiatric disorder that is a primary focus of clinical concern as confirmed by the M.I.N.I. 7.0.2.
Medications approved and/or employed off-label for cognitive dysfunction (e.g., psychostimulants).
Any medication for a general medical disorder that, in the opinion of the investigator, may affect cognitive function.
Use of benzodiazepines within 12 hours of cognitive assessments.
Consumption of alcohol within 8 hours of cognitive assessments.
Physical, cognitive, or language impairments sufficient to adversely affect data derived from cognitive assessments.
Diagnosed reading disability or dyslexia.
Clinically significant learning disorder by history.
Electroconvulsive therapy (ECT) in the last 6 months.
History of moderate or severe head trauma (e.g., loss of consciousness for >1 hour), other neurological disorders, or unstable systemic medical diseases that in the opinion of the investigator are likely to affect the central nervous system.
Pregnant and/or breastfeeding.
Received investigational agents as part of a separate study within 30 days of the screening visit.
Contact: Roger S. McIntyre, MD | 416-943-6284 | roger.mcintyre@uhn.ca
Mehala Subramaniapillai, MSc | m.subram@mail.utoronto.ca
Brain and Cognition Discovery Foundation (BCDF) Clinical Trial for Post-COVID-19 Cognitive Impairment (Toronto)
In order to meet the growing needs of a large portion of recovered COVID-19 patients suffering from ongoing cognitive challenges, the BCDF has initiated a clinical trial to evaluate the effectiveness of an existing, Health Canada-approved pro-cognitive antidepressant medication (Vortioxetine/Trintellix).
The Foundation is looking for adult participants with a past confirmed and documented COVID-19 infection who are suffering from subjective cognitive impairment to take part in this 8-week double-blind, placebo-controlled trial. Participants will be provided the medication by the research team and monitored by a physician throughout the trial. Participants will be provided a modest stipend for their time. This study is approved to be conducted by Health Canada and the Research Ethics Board.
You may be eligible if:
Aged 18-65 years
Have a confirmed prior COVID-19 diagnosis
Have been experiencing mental slowness since COVID-19 infection
Are able to attend 4 clinic visits in Toronto area
Contact: 647-450-8045 | longcovidbrain@gmail.com
Québec
Virtual Physical Rehabilitation Following COVID-19 Hospitalization (Montréal)
The purpose of this study is to investigate whether a timely, virtual home-based post-hospitalization physical rehabilitation program for COVID-19 patients who required hospitalization can improve functional mobility compared to usual care.
Inclusion Criteria:
(i) adult patients (>18 years old) who have been discharged from hospital due to COVID-19 infection and who have self-reported persisting symptoms of either reduced mobility, muscle weakness, dyspnea, or fatigue;
(ii) participants must be technologically capable of connecting (either independently or through household members) with an online videoconferencing platform through an e-mail invitation; and
(iii) be able to collaborate with the research assistant to complete the virtual assessment sessions or have a family member available to help.
Exclusion Criteria:
(i) pre-existing or newly identified severe cognitive impairment;
(ii) inability to speak or comprehend English or French;
(iii) known or self-reported acute and/or uncontrolled cardiac, musculoskeletal, or neurological condition that might render rehabilitation participation unsafe.
Contact: Tania Janaudis-Ferreira, PhD | 514-619-0871 | tania.janaudis-ferreira@mcgill.ca
Physical activity and sensory trainings to help COVID-19 patients recover from persistent smell and taste impairments – A pilot study (Montréal)
The primary objective of this study is to identify efficient treatments to help those with chemosensory losses due to COVID-19. To do so, 75 participants, men and women, aged 18 years old and above living in Canada will be recruited. Participants will be randomly assigned to one of the following three groups (25 in each group): physical activity, smell training, and control. Here is a quick summary of what participants in each group will have to do remotely during 12 weeks:
Physical activity group: Engage in physical activity for 12 weeks and wear a smart watch daily. Attend a 15-minute virtual meeting with a research professional every two weeks, that is six times during the 12 weeks.
Smell training group: Smell four odors twice a day for 12 weeks and evaluate their sensory perceptions via an online survey sent for each session specifically. Attend a 15-minute virtual meeting with a research professional every two weeks, that is six times during the 12 weeks.
Control group: Not change their usual routine for 12 weeks. Complete an online 15-minute follow-up questionnaire every two weeks, that is six times over the 12 weeks.
In addition, within each group, 10 individuals from Montreal, Quebec will be randomly selected to complete additional assessments in the laboratory. To distinguish this subgroup, it is called the "in-person subgroup." Participants will be assessed at the beginning of the intervention period, immediately after the intervention period, and 12 weeks after the end of the intervention period. The assessments include various questionnaires on sociodemographic data, physical and mental health, lifestyle habits, sensory dysfunction, nutritional preferences, as well as self-administered smell and taste tests sent by mail. The in-person subgroup only will have to do the following additional assessments: smell and taste tests using special equipment (olfactometer, gustometer, electroencephalogram) and online questionnaires on food intake for the day.
All participants will receive $ 40 as compensation for internet costs associated with the project. Participants in the physical activity group will be able to keep the smart watch. Participants in the chemosensory training group will be allowed to keep the samples. Participants in the control group will have the possibility to win one of five smart watches with a 30-minute training on how to use the watch and the benefits of physical activity on sensory complications due to COVID-19. Participants in the in-person subgroup, as compensation for costs incurred for their participation in the research project including parking fees, will receive 40$ per laboratory visit, for a total of $120. If you withdraw from the project or if your participation is ended before it is completed, the compensation will be proportional to the duration of your participation.
Inclusion Criteria:
Be 18 years old and above
Have had COVID-19 diagnosed by laboratory tests
Have recovered from COVID-19
Have persistent problems with your sense of smell and/or taste due to COVID-19 in the past 3 months or more (priority to participants with only this complication)
Have access to a computer and internet connection and be able to download the Zoom application
Have access to a smart phone ("texting" and Bluetooth)
Live in Canada
Exclusion Criteria:
Do 150 minutes or more of physical activity that makes you out of breath every week
Have limitations related to a training aiming at improving the sense of smell
Have physical limitations that may limit physical activity
Be part of another study that may influence the current study
Contact: Marie-Ève Mathieu, Associate Professor | (514) 343-6737 | me.mathieu@umontreal.ca
Thiffya A Kugathasan | Project Coordinator | thiffya.arabi.kugathasan@umontreal.ca
Institut de Recherche Cliniques de Montreal (IRCM) Post-COVID-19 (IPCO) Research Clinic (IPCO) (Montréal)
This is a prospective, observational cohort study to evaluate the short- and long-term end-organ complications of COVID-19 and to establish a COVID-19 biobank.
Inclusion Criteria:
Any gender, ≥ 18 years old
Current resident of Quebec
Speaks English or French
AND
1 of the following criteria:
COVID-19 positive test
Household members of a case who has tested positive for COVID-19
IRCM patients with a negative COVID-19 test result
Health care provider with a negative COVID-19 test result
Exclusion Criteria:
Any participant not deemed appropriate for enrollment according to the PI
Known pregnancy (female will not be automatically screened for pregnancy upon enrollment unless there is a possibility that they might be pregnant)
Contact:
Emilia Liana Falcone, M.D., Ph.D. | 514-987-5610 | Emilia.falcone@ircm.qc.ca
Amina Boubekeur, Ph.D.| 514-987-5581 | amina.boubekeur@ircm.qc.ca
Chile
Long-term Neurocognitive and Psychiatric Consequences in Severe COVID-19 Survivors (NPQCOVID) (Santiago)
Long-term neurocognitive and psychiatric consequences of COVID-19 remain mostly unknown to date. It has been reported that coronaviruses cause direct central nervous system infection (Needham et al. 2020). Besides that, new or worsening cognitive impairment commonly occurs and persists in survivors of intensive care unit (ICU) stay (Hosey & Needham. 2020).
The purpose of this study is to search and describe the cognitive and psychiatric long-term consequences of COVID-19 on patients who have been discharged from critical care units. This is an ambidirectional cohort study, that attempts to follow adults discharged from critical Care Units Adults due to COVID-19 up to 12 months after discharge, to evaluate the presence of cognitive impairment, linguistic and phonation function, depression, fatigue, functional gastroenterological symptoms, anxiety, or post traumatic disorder, and performance in activities of daily living and physical response to exercise as well.
Inclusion Criteria:
Adults over 18 years of age who have been hospitalized at critical care units, who were admitted for a diagnosis of COVID-19 and who present a score on the MOCA® cognitive test of less than 26 points at the time of hospital discharge .
Exclusion Criteria:
History of underlying cognitive disorder. History of underlying primary psychotic disorder. MOCA® cognitive test score greater than or equal to 26 points at the time of hospital discharge.
Contact: Constanza Caneo, MD | +56942909250 | cmcaneo@uc.cl
Carolina Mendez, PhD | +56 942595693 | carolinamendez@uc.cl
China
Long-term Outcomes in Patients With COVID-19 (Shanghai)
Long-term outcomes from coronavirus disease 2019 (COVID-19) are currently unknown. This study will collect daily living status of survivors of COVID-19.
Inclusion Criteria:
Survivors who had been admitted in Leishenshan Hospital for COVID-19 patients in Wuhan, China
Exclusion Criteria:
Patients who were < 18 years
Contact: Diansan Su, MD,PhD | +8618616514088 | diansansu@yahoo.com
Egypt
Implementation of Rehabilitation Program for Post COVID-19 (Assiut)
Many people who have suffered from the effects of COVID-19 might now be at risk of long-term impairment and disability. The extent of this impairment and disability is yet unknown, but it is clear from early research that these patients will be in need of rehabilitation in all phases of the disease - acute, post-acute and long-term.
Rehabilitation is defined as "a set of interventions designed to reduce disability and optimize functioning in individuals with health conditions in interaction with their environment." Rehabilitation might very well be a key strategy to reduce the impact of COVID-19 on the health and function of people.
Inclusion Criteria:
Post acute COVID-19 patients
Exclusion Criteria:
Acute COVID-10
Non- COVID-19 patients
Recent myocardial infarction
Recent pulmonary embolism
Neurologic diseases
Contact: Aliae A Mohamed-Hussein, MD | +201222302352 | aliaehussein@aun.edu.eg
Long-term Sequelae of COVID-19 (Myalgic Encephalomyelitis): An International Cross-Sectional Study (ME) (Alexandria)
The primary objective of this research is to understand acute and chronic long COVID symptoms by asking questions detecting patient's experience especially symptoms lasting for several months which is known as chronic fatigue syndrome(Myalgic encephalitis).
The study focuses on symptoms describing Myalgic encephalitis which may still affect COVID patients for several months after the infection along with making a big picture about rare symptoms that may the patient experienced during or after the infection.
A secondary objective of this research is to focus on the long-term sequelae effects and comorbidities following COVID-19 vaccination.
Inclusion Criteria:
Persons had a COVID-19 or suspected COVID-19 infection (still suffering or suffered symptoms) for longer than 1 week Even if your COVID-19 test result was negative, or you were not tested at all
Persons who are 18 years of age or older
Exclusion Criteria:
Persons other than selected in the Inclusion Criteria
Contact: Nour M Shaheen, Student | 01060038774 | nourshaheen40@gmail.com
Ahmed M Shaheen, Student | +20 101 099 1021 | ahmed.saad1704@alexmed.edu.eg
Germany
Visualizing Regional Lung Ventilation in Patients With Postacute-COVID-19 (ViReVentPoCov) (Jena)
In the absence of data on Electric impedance tomography of healthy spontaneous breathing patients that is compared to dyspnoeic patients suffering from post acute COVID-19 syndrome, the investigators contend that electrical impedance tomography provides additional clues to visualize regional lung ventilation and differentiate healthy from sick patients.
Inclusion Criteria:
for control group: no lung diseases, no allergic symptoms, non-smokers, over 18 years old
for patients with postacute COVID-19 syndrome: over 18 years, dyspnoeic symptoms
Exclusion Criteria:
heart pacemaker
epilepsy
BMI over 50
Contact: Jan-Christoph Lewejohann, Dr.med. | +49 3641 9322013 | jan-christoph.lewejohann@med.uni-jena.de
Philipp Reuken, Dr.med. | +49 3641 9324504 | philipp.reuken@med.uni-jena.de
Low-field Magnetic Resonance Imaging in Pediatric Post Covid-19 (FASCINATE) (Bavaria, Germany)
SARS-CoV-2 (Severe acute respiratory syndrome coronavirus type 2) is a new coronavirus and identified causative agent of COVID-19 disease. These viruses predominantly cause mild colds, but can sometimes cause severe pneumonia and pulmonary skeletal changes. By low-field gastric magnetic resonance imaging (NF-MRI), only a small number of structural, scarring changes were seen in a preliminary study of pediatric and adolescent patients with past SARS-CoV-2 infection. In contrast, however, extensive changes in ventilation and blood flow function of the lungs were seen.
The long-term consequences and spontaneous progression of these changes on imaging are completely unclear. The aim of this study is to assess the course of these functional lung changes in pediatric and adolescent patients and to validate them with other standard clinical procedures.
Control arm:
Inclusion Criteria:
Proof of SARS-CoV-2 infection and at least 2/3 times complete vaccination before infection (at least 14 days) (complete vaccination status according to German recommendations)
Long Covid criteria not met according to AWMF S1 guideline
Exclusion Criteria:
Acute SARS-CoV-2 infection and need for isolation
Necessary quarantine
Pregnancy, lactation
Indication of acute infection
Known pleural or pericardial effusion
Critical condition (need for respiratory support, ventilation, oxygen administration, shock, symptomatic heart failure)
Marked thoracic deformities
Previous lung surgery
Injuries that do not allow for physical stress testing
Refusal of MRI imaging
General contraindications to MRI examinations (e.g., electrical implants such as pacemakers or perfusion pumps, etc.)
History, clinical, or other suspicion of pulmonary disease
Current respiratory infection/symptomatology
Pain leading to respiratory limitation
Inhaled therapy (e.g., steroids or beta-mimetics)
Immunosuppression
Any condition that may lead to respiratory limitation (e.g., pain disorder)
Obesity (>97% of age percentile)
Recovered arm:
Inclusion Criteria:
Positive SARS-CoV-2 infection confirmed by PCR
Long Covid criteria not met according to AWMF S1 guideline
Exclusion Criteria:
Acute SARS-CoV-2 infection and need for isolation
Necessary quarantine
Pregnancy, lactation
Indication of acute infection
Known pleural or pericardial effusion
Critical condition (need for respiratory support, ventilation, oxygen administration, shock, symptomatic heart failure)
Marked thoracic deformities
Previous lung surgery
Injuries that do not allow for physical stress testing
Refusal of MRI imaging
General contraindications to MRI examinations (e.g., electrical implants such as pacemakers or perfusion pumps, etc.)
Long Covid arm:
Inclusion Criteria:
Positive SARS-CoV-2 infection confirmed by PCR
Long Covid criteria according to AWMF S1 guideline fulfilled
Exclusion Criteria:
Acute SARS-CoV-2 infection and need for isolation
Necessary quarantine
Pregnancy, lactation
Indication of acute infection
Known pleural or pericardial effusion
Critical condition (need for respiratory support, ventilation, oxygen administration, shock, symptomatic heart failure)
Marked thoracic deformities
Previous lung surgery
Injuries that do not allow for physical stress testing
Refusal of MRI imaging
General contraindications to MRI examinations (e.g., electrical implants such as pacemakers or perfusion pumps, etc.)
Contact: Ferdinand Knieling, MD | +49913185 ext 33118 | ferdinand.knieling@uk-erlangen.de
Pulmonary Vascular Dysfunction as a Cause of Persistent Exertional Dyspnea After Coronavirus Disease (COVID-19) (PulmVasC) (Giessen)
The purpose of this study is to identify pulmonary vascular disease in post/long-COVID-19 patients as a cause of dyspnea/exercise limitation and to differentiate it from other causes of dyspnea.
Inclusion Criteria:
Age ≥ 18 years, patients with a suspected diagnosis of post/long-COVID-19 syndrome who present to our pneumology or infectious disease outpatient clinic or corresponding ward from the start of the study and whose SARS-CoV-2 infection was diagnosed at least 3 and not longer than 18 months prior to presentation
Patients at least 3 and not longer than 18 months after a SARS-CoV-2 infection without post/long-COVID-19 syndrome who present to our post-infection outpatient clinic for follow-up
Exclusion Criteria:
Patients who refuse to participate in the study
Severe underlying chronic pulmonary, cardiac, or systemic disease (e.g., Chronic obstructive pulmonary disease (COPD), severe heart failure, neuromuscular disease) that was diagnosed prior to acute COVID-19 disease and whose progression appears likely as the cause of dyspnea
Other non pneumologic causes of dyspnea (e.g., hemoglobin < 100 g/L)
Unstable or acute disease (e.g., acute infection, acute renal failure, acute coronary syndrome)
Inability to perform spiroergometry, including transient orthopedic problems, contraindications to central venous and arterial catheter placement (e.g., severe bleeding tendency).
Contact: Natascha Sommer, PD | +0049-(0641) 985 56742 | Natascha.Sommer@innere.med.uni-giessen.de
Khodr Tello, PD | +0049-(0641) 985 56087 | Khodr.Tello@innere.med.uni-giessen.de
The Effect of Micellized Food Supplements on Health-related Quality of Life in Patients With Post-Acute COVID-19 Syndrome (Remote)
Food supplements like curcumin and boswellia serrata have been used traditionally for anti-inflammatory purposes. A well-known problem of these substances in their natural form is the low bioavailability. Micellization of these substances has been shown to increase the bioavailability significantly and thereby the clinical efficacy. The clinical value of these micellized substances has been presented in numerous clinical studies and in particular in patients with acute COVID-19. This study aims to examine the effect of a mixture of micellized curcumin, boswellia serrata and ascorbic acid on patients with long COVID.
The participants will be asked to take the micellized supplements daily, at home for 6 weeks. During this 6 weeks several questionnaires will be taken to asses general health-related quality of life. Follow-up measurements will be done at 24 weeks.
Inclusion Criteria:
Patients diagnosed with COVID-19 at least 28 days ago
Patients who are experiencing symptoms of long-COVID
18 years or older and younger than 85
Good understanding of written German
Exclusion Criteria:
Currently under pharmacological treatment for long-COVID
Any planned medical surgery or intervention where medication intake is necessary in the coming 3 months
Allergy to curcumin or Boswellia ( - Patients who are taking anticoagulants or have diabetes type I or II are only allowed to participate if their general practitioner is informed)
Contact: Maurice de Graaf, MSc | +32 530 52 84 | longcovid@physiometrics.ch
Liana S de Graaf | +41 79 936 57 77 | info@physiometrics.ch
Symptom-based Rehabilitation Compared to Usual Care in Post-COVID - a Randomized Controlled Trial (RELOAD)
Inpatient, multimodal rehabilitation represents one of the most important interventions in the disease management of post/long COVID. Different professional societies, including the German Society of Pneumology and the European Respiratory Society, recommend rehabilitation intervention to reduce the sequelae of COVID-19. However, from the perspective of science and practice, there are relevant areas that have been insufficiently investigated and are essential for the treatment success of post/long COVID patients:
Differentiation of rehabilitation effects from natural recovery after COVID-19.
Lack of personalized and symptom-based treatment approaches that can address the heterogeneity of symptoms in post/long COVID
Lack of uniform, high-quality rehabilitation standards in post-/long-COVID.
Therefore, post-COVID patients will be recruited at several post-COVID practices around Germany and randomized to receive (A) a rehabilitation program or (B) usual care.
The primary objective of this randomized controlled trial (RCT) is to investigate whether a 3-week symptom-oriented, inpatient, multidisciplinary rehabilitation intervention, whose content focus is standardized according to cluster assignment (fatigue, cognition, soma), has a positive effect on the quality of life (primary outcome) in post-COVID syndrome patients compared to a usual care group (standard outpatient care).
All study participants will be provided with a continuous telemonitoring system (SaniQ app) throughout the study period. After the interventional phase, there will be a 3 months follow-up assessment to evaluate the maintenance effects of COVID rehabilitation.
Inclusion Criteria:
Post-COVID Syndrome according to World Health Organisation definition (persistent symptoms for at least 3 months after PCR-test confirmed SARS-CoV 2 infection)
Exclusion Criteria:
no walking ability
not able to operate smartphone apps
rehabilitation program within the previous 6 months
Contact: Rainer Gloeckl, PhD | +49-8652-931630 | rgloeckl@schoen-klinik.de
Effects of Cranial Electrotherapy Stimulation on Anxiety of Patients After COVID-19
(Bavaria)
The aim of this study is to investigate the effect of cranial electrotherapy stimulation (CES), for one hour a day over 3 weeks of pulmonary rehabilitation (PR) on symptoms of anxiety in post-Covid patients.
Inclusion Criteria:
Group with anxiety:
High Beck Anxiety Inventory Score
≥18 years
Post SARS-CoV-2 infection
Written consent
Group without anxiety:
Low Beck Anxiety Inventory Score
≥18 years
Post SARS-CoV-2 infection
Written consent
Exclusion Criteria:
Active implants (cardiac pacemaker,...)
Pregnancy, lactation period
Contact: Dr. Andreas R. Koczulla | 0049-8652-932730 | rkoczulla@schoen-klinik.de
Tessa Schneeberger, MSc | 08652932730
[International]
COVID-19 Long Hauler Survey: Investigating the Role that Traditional Chinese Medicine (TCM) Plays in Post-COVID Conditions
This is an online medical research survey to investigate the role that Traditional Chinese Medicine (TMC) constitution plays in post COVID conditions. Symptoms, pre-existing conditions and Chinese medical constitution will be measured. Survey data will allow researchers to better understand why post-COVID conditions occur and why some individuals become 'long haulers'.
The survey can be completed by anyone age 18+ who has lingering COVID symptoms and/or hasn't completely recovered from COVID-19 at least 28 days after initial infection.
Contact: Dr. Jason Trombley DAOM, AP | info@longhaulersurvey.com
Fill out the ‘Contact Us’ form here.
Coronavirus and IBD Reporting Database
For those who suffer from IBD (Inflammatory Bowel Disease), please share this with your caregivers so they can join this registry for IBD patients and Covid. SECURE-IBD is an International, Pediatric and Adult database to monitor and report on outcomes of COVID-19 occurring in IBD patients. We encourage IBD clinicians worldwide to report ALL cases of COVID-19 in their IBD patients, regardless of severity (including asymptomatic patients detected through public health screening). This is being coordinated by UNC-Chapel Hill.
Inflammatory Bowel Disease (IBD) is an umbrella term used to describe disorders that involve chronic inflammation of your digestive tract including ulcerative colitis and Crohn's disease.
COVID-19 And Lingering Symptoms In Primary Care Patients (CALIP)
The signs and symptoms of SARS-CoV-2 infection vary and most people with COVID-19 experience illness of mild or moderate severity and recover with symptomatic treatment outside of hospital. Studies have found that some people experience lingering/long-lasting symptoms and only a minority of patients were completely free from COVID-19 related symptoms after two months. About one third still had up to two residual symptoms and 55% had three or more. As far as researchers know, no study on lingering symptoms has been published in patients after a mild or moderate infection managed in primary care settings. The aim of this study is to explore the course of disease over a one year period and describe lingering symptoms and their impact on well-being and daily activities in adult non-hospitalized patients with previous established COVID-19 infection.
Inclusion Criteria:
Confirmed SARS-CoV-2 infection, either by polymerase chain reaction (PCR), or by antigen testing (if authorized/recommended/used by national/local governments)
Symptoms consistent with mild to moderate COVID-19
Maximum of 2 weeks since positive SARS-CoV-2 test
Aged 18 years and older
Patient able and willing to comply with monthly phone calls.
Exclusion Criteria:
Hospitalisation due to COVID-19
Contact: Katarina Hedin | +46761303619 | katarina.hedin@rjl.se
Study Locations: Australia, Belgium, Brazil, France, Georgia, Germany, Ireland, Italy, Netherlands, Poland, Romania, Sweden, Ukraine, United Kingdom
Israel
Characterizing Long-term Cognitive and Emotional Impairment in Post-COVID-19 Sequelae (Petah Tikva)
A systematic characterization of the mental effects of COVID-19 will allow global healthcare systems to develop prevention and rehabilitation programs and provide psychological and/or psychiatric follow-up and intervention programs, according to circumstances. By elucidating the mechanisms underlying emotional and cognitive deficits in COVID-19 convalescents, this study may improve future management of the consequences of the pandemic, potentially contributing to the development of efficient medical treatments for populations who suffer from the long-term effects of the disease.
Inclusion Criteria:
Symptomatic individuals who recovered from COVID-19, 3-8 months after the onset of the acute stage of the disease. All individuals will be Israeli citizens, fluent Hebrew speakers with normal/corrected to normal vision and hearing abilities.
Exclusion Criteria:
Asymptomatic convalescents, and symptomatic convalescents who have a history of one or more of the following: Chronic obstructive pulmonary disease (COPD), Congestive heart failure (CHF), ischemic heart disease (IHD), Cerebrovascular accident (CVA), Chronic Kidney disease (CKD) with glomerular filtration rate of less than 30ml/minute, Cirrhosis of the liver, Hypoxia (less than 80% oxygen levels at room air), neurologic disease, diagnosed decline in cognitive function prior to disease onset , psychiatric disease or usage of anti-psychotic medications, addiction to drugs or alcohol.
In addition, a potential participant will be excluded from participation if he/she has a contraindication to magnetic resonance (MR) scanning, as defined by the Rabin Medical Center regulations: this includes patients with unremovable non-MR compatible implants, pregnant women and participants who suffer from claustrophobia.
Contact: Irit Shapira-Lichter, Dr | +97239376567 | iritsh7@clalit.org.il
Italy
Follow-up of Patients With Previous SARS-CoV-2 Infection: Long-term Damage Assessment (Naples)
People affected by SARS-CoV-2 infection, whether they have developed mild forms or a severe form of the disease, complain of nonspecific and entirely new symptoms or complain about the persistence of them. The study intends to follow over time the post-infectious phase of patients discharged from sub-intensive care unit. The aim of this study is to identify symptoms and their frequency of presentation in the SARS-CoV-2 population in the post-acute period.
Inclusion Criteria:
Patients over 18
Exclusion Criteria:
Patients under 18
Contact: Clara Balsano | 00390862434774 | clara.balsano@univaq.it
LOng COvid COmorbidities: Andrological, Reproductive, Sexual Dysfunctions in Patients Recovered From COVID-19 (Naples)
Considering the compelling amount of studies focused on patients in the active phase of COVID-19 disease and the scarcity of studies focused on patient cured from disease aimed at evaluating the sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, the purpose of the study is to investigate, in patients recovered from COVID-19 disease:
1) whether SARS-CoV-2 infection has induced in male patients, a primary (testicular) and / or secondary (pituitary) damage to the hypothalamic-pituitary-testicular hormonal axis, structural and / or functional damage to the testis and penis, sexual dysfunction or fertility disorders;
2) the prevalence in male and female patients of chemosensory symptoms (olfactory dysfunction) and assess whether there is a correlation between the prevalence, severity, duration and eventual persistence of olfactory dysfunction and the severity of COVID-19 disease.
Patients will be evaluated at baseline (at discharge from infectious and/or pneumology unit) and after 3- 12 months. A better definition of the prevalence and type of sequelae after recovery from COVID-19 disease could significantly improve the therapeutic management and long-term follow-up of these patients, with a relevant impact in terms of health resources and public health.
Inclusion Criteria:
Patients of both sexes recovered from SARS-CoV-2 infection (two negative nasopharyngeal swabs, negative IgM and positive anti SARS-CoV-2 IgG);
Aged over 18 years of age;
Ability to understand protocol procedures
Exclusion Criteria:
Any psychological/psychiatric/other medical conditions compromising the understanding of the nature and purpose of the study, and of its possible consequences
Uncooperative attitude of the patient
Contact: Rosario Pivonello, Prof. | 3317328474 | rosario.pivonello@unina.it
Long Covid Comorbidities: Endocrine, Metabolic, Neuropsychiatric, Muscle, Cardiovascular, Pulmonary, & Dermatologic Dysfunctions (LO-COCO) (Naples)
Considering the compelling amount of studies focused on patients in the active phase of COVID-19 disease and the scarcity of studies focused on patient cured from disease aimed at evaluating the long-term sequelae of SARS-CoV-2 infection, the purpose of this study is to investigate whether patients recovered from COVID-19 disease (SARS-CoV-2 infection) have: 1) endocrine-metabolic function damage; 2) neuro-psychiatric damage; 3) muscle damage; 4) pulmonary damage; 5) cardiological damage; 6) venous vascular damage; and/or 7) dermatological damage.
Patients will be evaluated at baseline (at discharge from infectious and/or pneumology unit) and after 3- 12 months. A better definition of the prevalence and type of long-term sequelae after recovery from COVID-19 disease could significantly improve the therapeutic management and long-term follow-up of these patients, with a relevant impact in terms of health resources and public health.
Inclusion Criteria:
Patients of both sexes recovered from SARS-CoV-2 infection (two negative nasopharyngeal swabs, negative IgM and positive anti SARS-CoV-2 IgG);
Aged over 18 years of age;
Ability to understand protocol procedures
Exclusion Criteria:
Any psychological/psychiatric/other medical conditions compromising the understanding of the nature and purpose of the study, and of its possible consequences
uncooperative attitude of the patient
Contact: Annamaria Colao, Prof | 3285390000 | colao@unina.it
Netherlands
Skeletal Muscle in PASC Patients (MUSCLE-PASC) (Amsterdam)
The primary aim of this study is to determine markers for skeletal muscle structure and function, and circulating factors, in patients with PASC, and compare with controls. The secondary objective is to determine skeletal muscle structure and function before and after induction of post-exertional malaise, and assess the relationships between the measures obtained from muscle biopsies and parameters of exercise tolerance.
Inclusion Criteria:
Non-hospitalized individuals with prior confirmed diagnosis of severe acute respiratory coronavirus 2 (SARS-CoV-2) infection by reverse transcription-polymerase chain reaction testing or serology (wantai) testing
Individuals with diagnosed PASC by a post-covid physician
>3 months of symptoms
Post exertional malaise, according to the DSQ-PEM questionnaire
No symptoms present before confirmed diagnosis of severe acute respiratory coronavirus 2
Aged between 18-65 years
For the healthy controls:
Aged between 18-65 years
Exclusion Criteria:
History of severe asthma, chronic obstructive pulmonary disease, stroke, congestive heart failure, heart surgery, or congenital heart diseases
Current treatment with drugs known to interfere with metabolism e.g. systemic corticosteroids, statins, SGLT2 inhibitors, GLP1 receptor agonists
Are current smokers or have been a regular smoker within the last 12 months
Insulin pump therapy
Symptomatic autonomic or distal neuropathy
BMI >30 due to adiposity with probably cause for a diffecult muscle biopsy.
Pregnancy
Recent acute myocardial infarction (<6 months)
Uncontrolled arrhythmia/severe conduction disorder (atrial fibrillation or second/third degree AV block) causing hemodynamic compromise
Implantable pacemaker or other cardiac device with complete ventricular pacing
Uncontrolled heart failure with hemodynamic compromise
Uncontrolled hypertension (Systolic Blood Pressure >150 mmHg and Diastolic Blood Pressure > 100 mmHg on repeated measurements)
Active infection, anaemia, severe renal dysfunction (estimated Glomerular filtration rate <30 ml/min/1,73m2) likely to significantly impact on exercise performance
Chronic illness (including orthopaedic, endocrinological, haematological, malignant, gastrointestinal, neurological, muscle or inflammatory disorders) likely to significantly impact on exercise performance
> 6 alcohol units per day or >14 alcohol units per week
Use of anticoagulants or anti platelet therapy
Contact: Michele van Vugt, Prof. | 020 566 9111 | m.vanvugt@amsterdamumc.nl
Brent Appelman, MD. | 020 566 9111 | b.appelman@amsterdamumc.nl
Norway
COVID-19 Related Lung Ventilation and Perfusion Injury (Hamilton)
Little is currently known about the immediate and long-term effect of COVID-19 on lung ventilation (delivery of air to the lungs) and lung perfusion (delivery of blood to the lungs). Some people who survive COVID-19 may have lung ventilation and/or perfusion injury that persists following COVID-19 recovery. This lung injury may be related to inflammation in the lung, breathlessness, exercise limitation and reduced quality of life.
Therefore, towards the goal of understanding the effects of COVID-19 on lung health, the purpose of this study is to characterize and understand the clinical relevance of COVID-19 related lung ventilation and perfusion injury and associated inflammatory status, ≤4 weeks and 6-months following COVID-19 recovery in an asthmatic and healthy population. To do this, an asthmatic and healthy population who have, and have not, been previously diagnosed with COVID-19 will be studied.
Inclusion Criteria:
For all participants:
Males and females ≥ 18 years of age
Individuals able and willing to provide written informed consent
Individuals able and willing to comply with the study protocol
For participants with asthma:
Individuals with physician confirmed asthma (12% bronchodilator reversibility or PC20 methacholine less than 8mg/ml)
Individuals treated with inhaled corticosteroids, oral corticosteroids and/or anti-T2 biologics
For participants who recently recovered from covid-19:
Individuals previously diagnosed with covid-19 confirmed by FLOQswab test
Individuals who recently (≤4-weeks) recovered from covid-19
Exclusion Criteria:
For all participants:
Males and females < 18 years of age
Individuals who are unable to read and/or understand English
Individuals who are pregnant or breastfeeding
Individuals who currently smoke or are an ex-smoker with ≥10 pack-year smoking history
Individuals who in the opinion of the investigator, are mentally or legally incapacitated, preventing informed consent from being obtained
Individuals who are unable to complete one or more study manoeuvres
For participants with no history of lung disease:
Individuals with a history of respiratory infection or disease
For participants who have not been diagnosed with covid-19:
Individuals who have previously had covid-19 confirmed by FLOQswab test
Contact: Sarah Svenningsen, PhD | +1 (905) 522-1155 ext 37313 | svennins@mcmaster.ca
Rehabilitation for Patients With Persistent Symptoms Post COVID-19 (Kvam Herad)
The aim of the study is to examine the feasibility and safety of a concentrated rehabilitation program with a mobile application follow-up for persons with persistent symptoms post COVID-19 infection. Researchers will examine recruitment availability, adherence to the program, goal achievement, and resources requirements.
Inclusion Criteria:
persistent symptoms minimum 2 months post COVID-19 infection
reduced exercise capacity level
symptoms of dyspnea and/or fatigue
Exclusion Criteria:
diseases where exercise is contraindicated (e.g. unstable angina pectoris)
drug abuse, severe mental illness where treatment in groups are contraindicated.
Contacts: Bente Frisk, PhD | +4797003111 | bente.frisk@hvl.no
Kiri L Njøten, MSc | +4797519412 | kilon@hvl.no
Portugal
Neuropsychological Sequelae and Long COVID-19 Fatigue (PostCoV2Psy) (Amadora)
An association of fatigue with post-viral neuropsychological disturbances has been reported. Among patients hospitalized with COVID-19 there is an increased incidence of anxiety and depression symptoms. In addition, a quarter of patients experience at least mild symptoms of acute post traumatic stress disorder. (Mazza, M. G. et al 2020). The prevalence of chronic fatigue syndrome had a correlation with post-traumatic stress disorder (PTSD) in a study conducted after the outbreak of the COVID-19 in Iran (Silmani et al, 2021), that showed 5.8% of subjects suffering from PTSD after 6 months of SARS-CoV-2 infection onset.
In this study, researchers propose to use a tool to quantify the degree of physical and psychological fatigue in post-COVID-19 patients, and assess the correlation of fatigue with the neuropsychiatric sequelae in hospitalized and non hospitalized patients.
Inclusion Criteria:
Patients who cumulatively meet the following criteria will be eligible for inclusion: (1) ≥18 years; (2) previous COVID-19 at least six months after the diagnosis duly documented in the clinical record; (3) persistent symptoms after cure criteria defined by WHO; and (4) symptomatic patients that attend the post-COVID-19 follow-up consultation of the study centres. All the study patients had COVID-19 confirmed by a positive real-time reverse-transcription polymerase chain reaction on a nasopharyngeal swab.
Exclusion Criteria:
(1) patients with PTSD or other severe psychiatric disorders documented in the clinical record (2) not able to respond the questionnaire (3) patients who had a concomitant neurological disorder (such as stroke, Alzheimer disease, Parkinson disease) will be excluded; (4) patients with persistent fatigue symptoms in the 6 months before SARS-CoV 2 infection.
Contact: Ligia Pires, MD | +351282450300 ext 43168 | alves1029@hotmail.com
Inês Simões, MD | +351282450300 ext 43066 | inesgsimoes@gmail.com
Long COVID-19 Fatigue and Obstructive Sleep Apnea (PostCov2OSA) (Faro)
The goal of the study is to identify the relationship of obstructive sleep apnea (OSA) prevalence with post COVID-19 fatigue that remains at least six months after acute disease.
Inclusion Criteria:
18 years;
Previous COVID-19 at least six months before the initial study protocol evaluation;
Persistent symptoms after cure criteria defined by WHO;
Patients who attend the post COVID-19 follow-up consultation of the study centers;
SARS-CoV-2 infection confirmed by a positive real-time reverse-transcription polymerase chain reaction on a nasopharyngeal swab;
Patients who agree to sign the written informed consent (following the ethics committee protocol).
Exclusion Criteria:
Patients who had a concomitant neurological disorder that could increase OSA risk (such as stroke, Parkinson disease, or amyotrophic lateral sclerosis);
Patients who were on invasive mechanical ventilation;
Patients with persistent fatigue symptoms in the 6 months before SARS-CoV 2 infection;
Patients without SARS-CoV-2 positive real-time reverse-transcription polymerase chain reaction on a nasopharyngeal swab.
Contact: Ligia Pires | +351282450300 ext 43168 | alves1029@hotmail.com
Tania Fatal | +351282450300 ext 35427 | taniafatal@hotmail.com
Spain
Rehabilitation for People With Post COVID-19 Syndrome (Grenada)
Patients who have undergone COVID-19 infection often have long-term sequelae. One of the most prevalent sequelae is pain. The main objective of this research is to investigate the efficacy of chronic pain multidimensional intervention in patients with post-COVID-19 syndrome on health-related quality of life, activity levels, pain knowledge and pain intensity
Inclusion Criteria:
Patients of both sexes.
Agreed to participate.
Post COVID-19 patients meeting the WHO definition for this disease.
Exclusion Criteria:
Neurological or orthopaedic pathologies that limited voluntary movement.
Cognitive impairment that prevented them from understanding and answering the questionnaires.
Patients suffering from a reinfection with SARS-CoV-2.
Patients who had been hospitalized due to COVID-19 infection.
Patients who had pre-existing chronic pain according to the current IASP definition.
Contact: Marie Carmen Valenza, PhD | 958 248035 | cvalenza@ugr.es
Prevalence of Long COVID-19 in the Canary Islands
The growing global burden of COVID-19 suggests that the potential effects of Long COVID in public health are vast even if Long COVID is experienced by a small proportion of patients recovering from acute infection.
The ability to identify patients at high risk for Long COVID and forecasting medical resource requirements is of important clinical utility in the present.
In view of the large number of people surviving after infection with COVID-19 and that should require follow-up, determine which patients are at risk of have Long COVID and who require close monitoring is crucial. In this study, therefore, the researchers set out to analyze what type of patient profile with COVID-19 who, after 12 weeks of having suffered the infection, experiences the signs and symptoms described by current literature.
Inclusion Criteria:
Have been positive for COVID-19 since the declaration of the state of alarm throughout the Spanish territory to deal with the health emergency situation caused by COVID-19 (March 14, 2020).
Symptoms associated with COVID-19 at least after 12 weeks of its detection.
Adequate cognitive and physical level to understand and perform the tests evaluation.
Exclusion Criteria:
Present comorbidities prior to suffering from COVID-19 whose symptoms are resemble Post-acute COVID-19.
Fibromyalgia.
Chronic fatigue.
Neuromuscular disease.
Not having signed the informed consent.
Person undergoing treatment for active cancer.
Contact: Aníbal Báez Suárez, PhD | +34652077692 | anibal.baez@ulpgc.es
Effectiveness of a Physical Therapy Telerehabilitation Program in Long Post COVID-19 Symptoms in Primary Health Care. (TPhysioCovid) (Madrid)
The aim of this study is to evaluate the effectiveness of a multimodal Physical Therapy telerehabilitation program in persistent post COVID-19 symptoms in Primary Health Care.
Inclusion Criteria:
Patients with long post-COVID symptoms (from week 12 to week 24).
Patients between 25 and 70 years old.
Patients with moderate respiratory and/or functional affectation with long post covid-19 symptoms, belonging to four Physiotherapy Units of primary Health Care in Madrid (Spain).
Confirmed diagnosis of COVID-19 via a positive nasopharyngeal or throat swab within the past 12 months.
Persistent symptoms lasting ≥12 weeks since the first positive test, including dyspnea (new or increased from baseline as measured by modified Medical Research Council (mMRC) score ≥1).
Normal oxygen saturation (greater than 90%) by pulse oximetry at rest on room air.
Participant owns a smart phone, tablet, or computer to access on-line sessions.
Exclusion Criteria:
People with symptoms such as fever, cough, upper respiratory distress, diarrhea, vomiting, anosmia or ageusia.
Temperature greater than 37.2ºC.
Patients with multimorbidity. Multimorbidity will be considered when the patient is diagnosed with two or more diseases among the following: diabetes, dyslipidaemia, cardiovascular disease (arterial hypertension, ischemic heart disease, valvular heart disease, heart failure), osteoarthritis, respiratory disease (asthma, chronic bronchitis), digestive disease ( gastric or duodenal ulcers, inflammatory bowel disease, liver disease), psychiatric pathology or tumor pathology.
Patients with previous pathologies: ischemic heart disease, dementia, lung failure, lung cancer, cystic fibrosis, pulmonary fibrosis, chronic kidney failure, liver diseases, myocardial arrhythmias, deep vein thrombosis, severe aortic stenosis, liver diseases.
Patients with weakened immune systems: in cancer treatment, organ or marrow transplant patients, HIV/AIDS, prolonged use of prednisone or similar medication.
Patients with functional limitations to carry out their basic activities of daily living. Barthel index greater than 90.
Patients with cognitive problems. Mini-Cognitive Lobo exam greater than 23 points
Active bleeding.
Unstable fractures.
Contact: José Calvo Paniagua, Master | joscalvi@hotmail.com
María José Díaz Arribas, PhD | +0034 913941545 ext 1545 | mjdiazar@med.ucm.es
Sweden
Internet-based Multidisciplinary Rehabilitation for Longterm COVID-19 Syndrome (COVID-19) (Stockholm)
Internet-based multidisciplinary interventions will be offered to participants suffering from longterm COVID-19 syndrome. Data will be collected by internet platform at Karolinska Institutet (BASS) before, after rehabilitation and at follow-up after 6 months. Both self-scored questionnaires and physical tests performed at home will be collected to understand the symptomatology, functioning and activity level. Rehabilitation during 8 weeks period will be given in groups as face-to-group, pre-recorded film sessions and by individual approach, the participants will use ExorLive app for physical activity.
Inclusion Criteria:
Confirmed COVID-19 infection
Post-infection symptoms lasting longer than 3-6 months
Clinically stable persons regarding symtoms or other co-morbidities
Ability to participate in internet-based rehabilitation in group in Swedish.
Exclusion Criteria:
Uncertainty regarding covid-19 infection or co-morbidities started or exacerbated during the same time
Alcohol and drug abuse
Untreated psychiatric and somatic co-morbidities
Undergoing medical or psychotherapeutic treatment or rehabilitation which can interact with rehabilitation outcomes.
Contact:
Indre Bileviciute-Ljungar, Associated professor | +46858703158 | indre.ljungar@ki.se
Kristian Borg, professor | +46812355000 | kristian.borg@ki.se
Safety and Efficacy of Hyperbaric Oxygen Therapy for Long COVID Syndrome (HOT-LoCO) (Stockholm)
This study explores hyperbaric oxygen administered in a randomized placebo-controlled clinical trial as a potential treatment for patients suffering from Long COVID.
The overall hypothesis to be evaluated is that hyperbaric oxygen (HBO2) alleviates symptoms associated with Long COVID.
Inclusion Criteria:
Aged 18-60 years
Healthy or mild systemic disease (ASA 1-2) prior to COVID-19
Symptoms consistent with Long COVID for at least 12 weeks
Diagnosed with Long COVID, PACS, PCS (ICD-10 U09.9)
Working or studying prior to COVID-19
Documented informed consent according to GCP and national regulations
Exclusion Criteria:
Known pregnancy or positive pregnancy test in women of childbearing age
ASA 3 or more from other cause than Long COVID
Score above 70 in RAND-36 Role Limitation Physical Health (RP) or Physical Functioning (PF)
Diabetes
Diagnosed with hypertension prior to COVID-19
Contraindication for hyperbaric oxygen treatment according to local guidelines
Participation or recent participation in a clinical trial with an investigational product
Mental inability, reluctance or language difficulties that result in difficulty understanding the meaning of study participation
Contact: Anders Kjellberg, MD | 0760657355 | anders.kjellberg@ki.se
Switzerland
Characteristics of Long COVID-19 Syndrome (Zurich)
The purpose of this study is to collect personal health data of patients with long COVID syndrome including symptoms, medical history and persistent organ damage.
Inclusion Criteria:
Long COVID syndrome
Age >= 18 years
Informed consent
Exclusion Criteria:
None
Contact: Christian F Clarenbach, MD | +41 44 255 17 12 | christian.clarenbach@usz.ch
Stefan Malesevic, MD | +41442551743 | stefan.malesevic@usz.ch
The Effect of Micellized Food Supplements on Health-related Quality of Life in Patients With Post-Acute COVID-19 Syndrome (Remote)
Food supplements like curcumin and boswellia serrata have been used traditionally for anti-inflammatory purposes. A well-known problem of these substances in their natural form is the low bioavailability. Micellization of these substances has been shown to increase the bioavailability significantly and thereby the clinical efficacy. The clinical value of these micellized substances has been presented in numerous clinical studies and in particular in patients with acute COVID-19. This study aims to examine the effect of a mixture of micellized curcumin, boswellia serrata and ascorbic acid on patients with long COVID.
The participants will be asked to take the micellized supplements daily, at home for 6 weeks. During this 6 weeks several questionnaires will be taken to asses general health-related quality of life. Follow-up measurements will be done at 24 weeks.
Inclusion Criteria:
Patients diagnosed with COVID-19 at least 28 days ago
Patients who are experiencing symptoms of long-COVID
18 years or older and younger than 85
Good understanding of written German
Exclusion Criteria:
Currently under pharmacological treatment for long-COVID
Any planned medical surgery or intervention where medication intake is necessary in the coming 3 months
Allergy to curcumin or Boswellia ( - Patients who are taking anticoagulants or have diabetes type I or II are only allowed to participate if their general practitioner is informed)
Contact: Maurice de Graaf, MSc | +32 530 52 84 | longcovid@physiometrics.ch
Liana S de Graaf | +41 79 936 57 77 | info@physiometrics.ch
Taiwan
Using Mixed-methods Approach to Explore the Long-term Effects of COVID-19 (Taipei)
The specific aims of this study are to (1) expand scientific understanding of Long COVID, (2) gather data on the development of various symptoms and HRQOL (Health-related Quality of Life) after 3, 6, 9, and 12 months of COVID-19 diagnosis, (3) explore predicting factors of the existence and severity of Long COVID, and (4) explore how patients experience COVID-19 symptoms.
Inclusion Criteria:
at least 20 years-old
diagnosed with COVID-19 within six months
Exclusion Criteria:
are still in the active phase of COVID-19 infection (i.e., diagnosed within 4 weeks)
have cognitive impairment or other issues that prevents them from doing self-ratings of symptoms via phone interviews
Contact: Chia Chun Tang, PhD | +886-2312-3456 ext 88436 | chiatang@ntu.edu.tw
United Kingdom
England
Musculoskeletal Pain in Long COVID (MUSLOC) (Leeds)
This longitudinal study will explore the long COVID musculoskeletal pain etiology, pathophysiology, impact on function and quality of life, prognosis and its natural evolution.
Inclusion Criteria:
Individuals who have tested positive for COVID-19 or self-reported symptoms of COVID-19 confirmed by an independent clinician.
New onset musculoskeletal pain that develops during or following an infection consistent with COVID-19, continues for 4 weeks or more and is not explained by an alternative diagnosis.
Age 18 years or older.
Ability of participants to understand and the willingness to sign a written informed consent document.
Stated willingness to comply with all study procedures and availability for the duration of the study.
Ability of participants to read and understand English.
Exclusion Criteria:
People with pre-covid chronic pain syndrome.
Unable to provide informed consent.
Specific exclusion for Electroencephalogram (EEG): Patients with history of epileptic seizures.
Contact: Manoj Sivan, MD | 01133922564 | m.sivan@leeds.ac.uk
Ai Lyn Tan, FRCP | 01133438545 | a.l.tan@leeds.ac.uk
HElping Alleviate the Longer-term Consequences of COVID-19 (HEAL-COVID) (HEAL-COVID) (Cambridge)
HEAL-COVID aims to evaluate the impact of treatments on longer-term morbidity, mortality, re-hospitalisation, symptom burden and quality of life associated with COVID-19.
The first two treatment arms are Apixaban and Atorvastatin, with further treatment arms to be added at the direction of the UK COVID-19 Therapeutic Advisory Panel (UKCTAP).
Inclusion Criteria:
Greater than or equal to 18 years of age.
Hospitalised with estimated hospital discharge within 5 days.
SARS-CoV-2 infection associated disease (laboratory confirmed SARS-CoV-2 infection) on this hospital admission.
Written informed consent obtained from participant or participant's legal representative.
Exclusion Criteria:
Known hypersensitivity to trial medication (patient will be excluded from specific arm).
Long-term pre-hospital administration of trial medication (patient will be excluded from specific arm).
Previous medical history of significant complication with trial medication or trial medication drug class.
Medical history that might, in the opinion of the attending clinician, put the patient at significant risk if he/she were to participate in the trial.
Participant not expected to survive 14 days from hospital discharge.
Contact: HEAL-COVID Team | +44 (0) 151 794 0222 | trial.team@heal-covid.net
'Long COVID' in Suffolk and North Essex: Defining the Disease and Optimising Outcomes (Ipswich, Suffolk)
The purpose of the study is to accurately describe the rehabilitation needs of individuals with post-COVID-19 syndrome up to 36 months after infection, allowing better diagnosis, triage and resource management. A major focus will be the impact on everyday life to return to normal activities.
Inclusion criteria:
Individuals 18 years old and over (no upper age limit)
Male and female
Diagnosed with COVID-19 via PCR testing Or,
Experienced symptoms of COVID-19 (new continuous cough, a high temperature, loss of taste and smell) AND clinically diagnosed with Post-COVID-19 Syndrome by their GP Participants who live within Suffolk and North East Essex
Exclusion criteria:
Individuals unable to consent for themselves
Individuals without sufficient proficiency in English language to take part in telephone or video call, where the research team have been unable to make adjustments to enable their participation
Individuals under 18 years old
Contact: ESNEFT R&D Manager | 01473 703885 ext 5885 | R&D@esneft.nhs.uk
HEART Rate Variability Biofeedback in Long COVID-19 (HEARTLOC) (HEARTLOC) (Leeds, Yorkshire)
Long COVID can produce a vast array of symptoms including fatigue, breathlessness, fast heart rate, blood pressure disturbance, temperature disturbance, and dry mouth. Many of these symptoms could be explained by the nervous system being predominantly in a stress or 'fight or flight' response, also known as dysautonomia.
One way of assessing whether this is the case is by measuring heart rate variability (HRV). This is the time variation between heart beats and is a marker of how stressed the nervous system is or how strong is the 'fight or flight' response. Heart rate variability can be measured using devices which are worn round the wrist or attach to the chest. An increased variability in heart rate corresponds with a more relaxed nervous system and decreased variability with a more stressed nervous system. Monitoring HRV in real-time and implementing interventions such as a breathing regime to maximise HRV is known as HRV biofeedback.
The body can be trained out of the fight or flight response and into the 'rest and digest' mode response of the nervous system in this way and potentially significantly improve symptoms. The study’s researchers propose that for people with Long COVID, a programme of structured breathing exercises over 4 weeks whilst tracking HRV can demonstrate an improvement in HRV and consequently improve Long COVID symptoms.
Inclusion Criteria:
Age > 18 years
Confirmed Long COVID based on a positive PCR or antibody test and Long COVID symptoms as per the NICE criteria for post-COVID syndrome
Current Leeds COVID Rehabilitation service user
Self-rating of 'moderate/severe' on the Leeds COVID Rehabilitation Service Long COVID participant reported outcome measure (known as C19-YRS)
Abnormal NASA Lean Test (NLT)
Exclusion Criteria:
Age < 18 years
Unable to use the wearable or smartphone app technology
Cognitive problems or mental health disorders causing inability to consent
Cardiac arrhythmia (current or prior tachyarrhythmia or bradyarrhythmia)
Existing significant cardiorespiratory disease which might be expected to affect studied symptoms of palpitations, presyncope, breathlessness and fatigue (asthma not included in this definition)
Contact: Manoj Sivan, MD | 01133922564 | m.sivan@leeds.ac.uk
The UK Interstitial Lung Disease Long-COVID19 Study (UKILD-Long COVID): Understanding the Burden of Interstitial Lung Disease in Long COVID (London)
Prospective observational study of hospitalised and non-hospitalised patients post- infection with SARS-CoV-2. The study aims to recruit 2000 individuals, with proven COVID-19, who were not hospitalised but presented to Long-COVID clinics with persistent respiratory symptoms such as breathlessness or cough and are referred for cross-sectional imaging (computer tomography, CT) at baseline (3 months weeks after their first COVID-19 symptoms). The study will run for 18 months.
Inclusion Criteria:
Age >18 years old -99 years old
Evidence of SARS-CoV-2 infection confirmed by PCR or serology 3 months (+/- 6 weeks) earlier
Clinical indication for a chest CT scan as per clinician judgment
Exclusion Criteria:
Life-limiting illness within 12 months
Significant pre-existing lung disease prior to March 2020, which in the investigator's judgement could make the chest CT scans difficult to interpret
Contact: Mark Weeks, Dr. | +44 (0)20 7594 7972 ext 47972 | m.weeks@imperial.ac.uk
The Effects of The Jing Method of Advanced Clinical Massage on Symptoms of Long Covid in Adults Aged 18 and Over (London)
Research shows that Massage Therapy has beneficial effects on breathing dysfunctions such as COP, depression, autoimmune conditions, and fibromyalgia. These are all conditions that share symptoms with Long Covid.
The aim of this project is to establish whether Clinical Massage can help to improve the lives of people suffering from Long Covid, by reducing symptoms of fatigue, dyspnoea, and cognitive impairment. Participants will undergo a 6-week control period followed by 6 weeks of intervention.
During the first 6 weeks, subjects will complete the Covid-19 Yorkshire rehabilitation scale questionnaire online. A 6-week hands-on intervention will follow, where the subjects will fill in the Covid-19 Yorkshire rehabilitation scale questionnaire prior to receiving a 30min hands-on treatment.
Adults over the age of 18 who have been experiencing recurring symptoms of Long Covid for at least 12 weeks since recovery from Covid-19 are eligible to participate in this study.
Symptoms must include:
Fatigue
Dyspnoea
Cognitive impairment
Exclusion criteria:
Pregnancy
Currently testing positive for Covid-19
ME/CFS diagnosis
New onset of breathlessness, heart palpitations or any other cardiovascular symptoms
Contact: Danila Ciencia | danila.sen.massage@gmail.com | 07951 716 108
Recovering From COVID (OVER-COVID) (London)
Following the success of pilot data trialing a virtual community-based remote monitoring model, using Bluetooth enabled pulse oximeters, which demonstrated a saving of 300 bed spaces over a three week period, a nationwide expansion is set to be implemented through NHS Digital.
Study Population
Discharged from hospital with a RT-PCR SAR-CoV-2 positive swab result.
Inclusion Criteria:
Aged 18 years or over.
Able to provide written consent.
Exclusion Criteria:
Any participants that withdraw their consent.
Any form of psychiatric disorder or a condition that, in the opinion of the investigator, may hinder communication with the research team.
Inability to cooperate or communicate with the research team.
Contact: Fahad M Iqbal, MBChB | f.iqbal@imperial.ac.uk
Scotland
CISCO-21 Prevent and Treat Long COVID-19. (CISCO-21) (Glasgow)
Many people have long-lasting symptoms after COVID-19, such as breathlessness, fatigue and chest pain. So far, research studies of treatments for COVID-19 have focused on the life-threatening acute illness; few studies look at treatments to improve long-term health after COVID-19. COVID-19, particularly when this requires a hospital admission, can lead to weight loss and muscle wasting, contributing to worse outcomes. Muscle strengthening (resistance-based) exercise could improve outcomes in the long-term and is the focus of this study.
Inclusion Criteria:
Virology polymerase chain reaction (PCR) positive laboratory diagnosis of COVID-19,
Within 6 months of diagnosis,
Persistent symptoms for at least 4 weeks from symptoms onset (Groups A & B only)
Presentation type - one of group A, B or C;
Exclusion Criteria:
Physiotherapy as part of standard care e.g. post intensive care unit (ICU), post high dependency unit (HDU),
No expectation of being able to walk within 3 months
Unable to provide informed consent,
Unable to comply with the protocol.
Known pregnancy
Contact: Diann Taggart | 44 141 314 4407 | Diann.Taggart@ggc.scot.nhs.uk
